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Abstract 
 
In order to examine the impact of excipients, packaging  systems and storage 
conditions on  acetylsalicylic acid stability in different 75mg aspirin tablets, 
23   and 32 full factorial designs were adopted for the development of 
acetylsalicylic acid chewable and effervescent tablets, respectively.  
The study revealed that most of excipients have a profound influence in 
physicochemical behaviors of aspirin tablets. Due to their hygroscopicity, 
PVP, starch, sodium bicarbonate and sorbitol were shown to affect the 
hardness, weight variation, friability, free salicylic acid and content percent 
of aspirin in both chewable tablets and effervescent tablets. Using 
combination of mannitol and sorbitol in different ratios, as filler in chewable 
tablets has resulted in lowering the cost of the formulations with enhanced 
product stability. 
Both blister and strip packaging systems showed no significant difference 
(cp ≥ 0.05) with regard to dosage form protection in case of chewable tablets 
where no added moisture protection was observed with PVC blister pack.   
It has been shown that effervescent tablets manufacturing process involves 
some critical steps which need to be addressed carefully during formulations 
and factory design. 
The conventional aspirin tablets formulated with starch, saccharin sodium 
and talc where found to have undesirable physical characteristics. 
Among the three tablet dosage forms of aspirin 75mg, the chewable tablets 
were found to be the best. From this, one formula was selected, modified by 
using a combination of mannitol and sorbitol as filler and  finally upgraded 
by the study of the particle size range, powder flow, mixing process and 
selection of a suitable manufacturing process. Two batches of upgraded 
formula were subjected to six months accelerated stability study and were 
found to be stable. 
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 ﻣﻠﺨﺺ اﻻﻃﺮوﺣﺔ
 
اﻟﻔﻮارة  ﻎ واﻻﻗﺮاص ﻟﺘﻄﻮﻳﺮ اﻗﺮاص اﻟﻤﻀ²3،³2 اﻟﺘﺼﻤﻴﻢ اﻹﺣﺼﺎﺋﻲﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ ﺗﻢ إﺳﺘﺨﺪام 
هﺬا اﻟﺤﻤﺾ ﻓﻲ ﻋﻠﻲ ﺛﺒﺎت ﻧﻈﻢ اﻟﺘﻌﺒﺌﺔ وﻇﺮوف اﻟﺘﺨﺰﻳﻦ ،اﻟﻤﻀﺎﻓﺎت وذﻟﻚ ﻟﺪراﺳﺔ ﺗﺄﺛﻴﺮﻟﻼﺳﺒﺮﻳﻦ 
  . ﻣﻠﺠﻢ57اﻗﺮاص ﻣﺨﺘﻠﻔﺔ ﻟﻸﺳﺒﺮﻳﻦ 
 اﻟﺨﻮاص  ﻋﻠﻰﺢ واﺿ ﻟﻬﺎ ﺗﺄﺛﻴﺮﻟﻤﻀﺎﻓﺎت او اﻟﺼﻮاﻏﺎتاوﺿﺤﺖ اﻟﺪراﺳﺔ ان آﺜﻴﺮ ﻣﻦ ا
ﻣﺜﻞ ) ﻠﺮﻃﻮﺑﺔ ﻣﻦ اﻟﺠﻮاﻟﻤﻀﺎﻓﺎت اﻟﻤﺎﺻﺔ ﻟ.  اﻟﻤﺨﺘﻠﻔﺔﺳﺒﺮﻳﻦﻴﻤﻴﺎﺋﻴﺔ ﻷﻗﺮاص اﻷﻜاﻟوﺋﻴﺔاﻟﻔﺰﻳﺎ
ﺗﻐﻴﺮ ،هﺸﺎﺷﺔ ، ﻋﻠﻰ ﺻﻼﺑﺔأﻇﻬﺮت ﺗﺎﺛﻴﺮ واﺿﺢ (اﻟﻨﺸﺄ،اﻟﺴﻮرﺑﺘﻮل، ﺑﻴﻜﺮﺑﻮﻧﺎت اﻟﺼﻮدﻳﻢ واﻟﺒﻮﻓﻴﺪون
  . واﻻﻗﺮاص اﻟﻔﻮارةاص اﻟﻤﺪغ ﺔ ﺣﺎﻣﺾ اﻟﺴﺎﻟﺴﻠﻴﻚ اﻟﻤﺘﺤﺮرة ﻓﻲ أﻗﺮﻣﺤﺘﻮى اﻻﺳﺒﺮﻳﻦ وآﻤﻴ،اﻟﻮزن
 آﻤﺎدة ﻣﺎﻟﺌﺔ ﻓﻲ أﻗﺮاص اﻟﻤﺪغ وﺟﺪ أﻧﻪ  ﺧﻠﻴﻂ ﻣﺎدﺗﻲ اﻟﺴﻮرﺑﺘﻮل واﻟﻤﺎﻧﻴﺘﻮل ﺑﻨﺴﺐ ﻣﺘﻔﺎوﺗﺔإﺳﺘﺨﺪام
  .ﻧﺘﺎج وزﻳﺎدة ﺛﺒﺎت اﻟﻤﺴﺘﺤﻀﺮﺗﻘﻠﻴﻞ ﺗﻜﻠﻔﺔ اﻹ،  ﺑﺪورﻳﻦ مﻮﻳﻘ
ﻣﻦ ﻒ ﻋﺪم وﺟﻮد اﺧﺘﻼف ﺑﻴﻦ ﺎرﻳﻈﻣﺷﺮﻃﺔ وأﻧﻈﻤﺔ اﻟﺘﻐﻠﻴﻒ ﻣﻦ أ أﻇﻬﺮت  ﻓﻲ ﺣﺎﻟﺔ أﻗﺮاص اﻟﻤﺪغ،
إي ﻮﻓﺮﻟﻢ ﺗ اﻟﺒﻮﻟﻲ ﻓﻴﻨﺎﻳﻞ آﻠﻮراﻳﺪ ﺷﺮﻃﺔ اﻟﻤﺼﻨﻌﺔ ﻣﻦ ﻣﺎدةن اﻷﻷ ﺣﻴﺚ ﺣﻤﺎﻳﺔ اﻟﺸﻜﻞ اﻟﺼﻴﺪﻻﻧﻲ
  . اﻟﺠﻮﻣﺘﺼﺎص رﻃﻮﺑﺔ  ﻣﻦ إﺣﻤﺎﻳﺔ
ﺗﺼﻨﻴﻊ وﺗﺤﻀﻴﺮ اﻻﻗﺮاص اﻟﻔﻮارة ﻳﺤﺘﺎج اﻟﻲ ﻇﺮوف ﻣﻌﻴﻨﺔ ﻻﺑﺪ ﻣﻦ ﻣﺮاﻋﺎﺗﻬﺎ ﻟﺬﻟﻚ ﻻﺑﺪ ﻣﻦ ﺗﺼﻨﻴﻌﻬﺎ 
  .ﻓﻲ ﻏﺮف ﻣﺤﻜﻤﺔ اﻟﺮﻃﻮﺑﺔ اﻟﻨﺴﺒﻴﺔ ودرﺟﺔ اﻟﺤﺮارة وﺗﻌﺒﺌﺘﻬﺎ ﻓﻲ ﻋﺒﻮات ﻣﺤﻜﻤﺔ اﻻﻏﻼق 
ﻇﻬﺮت ﺧﺼﺎﺋﺺ  اﻟﺼﻮدﻳﻮم وﺑﺪرة اﻟﺘﻠﻚ أﺳﻜﺮﻳﻦ،ﺳﺒﺮﻳﻦ اﻟﻌﺎدﻳﺔ اﻟﻤﺼﻨﻌﺔ ﻣﻦ اﻟﻨﺸﺄ ﻗﺮاص اﻻأ
 اﻟﺘﺼﻨﻴﻊ ﻓﻬﻲ ﺗﻌﺎﻧﻲ ﻣﻦ اﻟﻬﺸﺎﺷﺔ واﻟﻀﻌﻒ ﻋﻨﺪ،آﻤﻴﺎﺋﻴﺔ ﻏﻴﺮ ﻣﺮﻏﻮﺑﺔ ﻣﻦ ﺧﻼل اﻟﺪراﺳﺔ ﻓﺰﻳﻮ
  .واﻟﺘﺨﺰﻳﻦ ﻟﻔﺘﺮات ﻃﻮﻳﻠﺔ
اص اﻟﻤﺪغ  ﻓﺈن أﻗﺮﻟﻠﻤﺪغ واﻟﻌﺎدﻳﺔ،اﻟﻔﻮارة ،  ﻣﻠﺠﻢ 57ﺳﺒﺮﻳﻦ دراﺳﺔ اﻷﻧﻮاع اﻟﺜﻼث ﻷﻗﺮاص اﻷﻋﻨﺪ 
ﻓﻀﻞ ﺻﻴﻐﺔ وﺗﺤﺴﻴﻨﻬﺎ ﺑﺈﺳﺘﺨﺪام ﺧﻠﻴﻂ اﻟﺴﻮرﺑﺘﻮل واﻟﻤﺎﻧﻴﺘﻮل اﻷﻓﻀﻞ وﻣﻨﻬﺎ ﺗﻢ إﺧﺘﻴﺎر أوﺟﺪت 
ﻠﻴﺔ اﻟﺨﻠﻂ اﻟﺠﺮﻳﺎن وﻋﻤ،ﺣﺠﺎم اﻟﺠﺴﻴﻤﺎت ﻄﺒﻴﻖ دراﺳﺎت أوﺗﺮﻓﻴﻌﻬﺎ ﻟﺘﺼﻨﻊ ﺑﻜﻤﻴﺎت آﺒﻴﺮة وذﻟﻚ ﺑﺘ
  . اﻟﺘﺼﻨﻴﻊ اﻟﻤﺜﻠﻰ إﺧﺘﻴﺎر ﻃﺮﻳﻘﺔآﻤﺎ ﺗﻢ ، ﻟﻠﺒﺪر
  .آﺜﺮ ﺛﺒﺎﺗﺎﻦ ﻣﻦ اﻟﺼﻴﻐﺔ اﻟﻤﻄﻮرة وﻗﺪ وﺟﺪﺗﺎ أﻴﻟﺘﺸﻐﻴﻠﺘﺷﻬﺮ دراﺳﺔ ﺛﺒﺎت ﻣﺘﺴﺎرع ﻟﻤﺪة ﺳﺖ أﺖ أﺟﺮﻳ
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 1. Literature Review  
 
1.1. Tablet Dosage Form: 
The oral route of drug administration is the most important method of 
administering drugs for systemic effects. It is probable that at least 90% of 
all drugs used to produce systemic effect are administered by the oral route 
(Singh and Naini, 2002). 
Solid dosage forms represent the preferred class of drugs that are 
administered orally. The reasons for this preference are: 
-Represent unit dosage form. 
-Less expensive. 
-Taste masking of the drugs is easy. 
-Easy to handle.  
-Stability of the drugs in solid dosage forms is higher than in liquid dosage 
forms. 
-No preservation requirements (Singh and Naini, 2002).  
Tablets and capsules are the two commonly used oral solid dosage forms 
and in fact there are many advantages of tablets over capsules including the 
tamper evidence, the lower cost of production, the greatest dose precision, 
the least content variability and the ease of application and fabrication of 
many controlled release products in the tablet form (Singh and Naini, 
2002).   
The major disadvantage of tablets is attributed to some drugs which are 
compression resistant, having poor wetting tendency, of low aqueous 
solubility, having unacceptable organoleptic properties or suffering 
climatic-based instability. In these cases design of such drug into tablet 
form necessitates additional coating technique which, compared to capsule, 
is high cost approach (Banker and Anderson, 1986) 
 
1.1.1. Tablet classification: 
Tablets can be classified by their route of administration or function, by the 
type of drug delivery system they represent within that route and by their 
form and method of manufacture.  
Based on the route of administration, tablets can be classified into 
compressed tablets for oral ingestion (buccal tablet, sublingual tablets, 
troches, lozenges, dental cones and mouth dissolving tablets), 
implantations which are placed surgically under the skin and tablets for 
insertion into natural body orifices (vaginal tablets). However, based on 
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their drug release characteristics, tablets can be categorized into 
immediate, modified and controlled release tablets. 
 
1.1.1.1. Immediate release tablets: 
 In this case, loaded drug is intended to be released rapidly after 
administration, or the tablet is dissolved and administered as a solution. It 
is the most common type of tablets dosage forms which includes 
disintegrants to aid in the quick drug release. This category includes 
uncoated tablets, chewable tablets, effervescent tablets, sublingual tablets, 
mouth dissolved tablets and buccal tablets (Aulton, 2002). 
 
1.1.1.2. Modified release tablets: 
These are normally swallowed intact, whereas the drug is released slowly 
at constant rate in order to sustain the duration of action, the tablets might 
be termed as extended release tablets or sustained release tablets. On the 
other hand, tablets might be named as delayed release tablets if the loaded 
drug is liberated from the tablets some time after administration and after 
this lag time the release is normally rapid. The most commonly applied 
type of delayed release tablets is the enteric coated tablet (Aulton 2002). 
 
1.1.1.3. Controlled release tablets: 
For controlled release tablets, the release of drug proceeds at a rate profile 
that is not only predictable kinetically, but also reproducible. Controlled 
release tablet can be subdivided into rate preprogrammed drug delivery, 
activation modulated drug delivery, feedback regulated drug delivery and 
site-targeting drug delivery tablets (Chien, 2005). 
 
1.1.2. Tablet formulation 
The objective of the design and manufacture of the compressed tablet is the 
oral delivery of the correct amount of drug in the proper form at the proper 
time in the desired location and, moreover, to have its (the drug) chemical 
integrity protected to that point. Therefore, a tablet should be an elegant 
product having its own identity while being free of defects such as chips, 
cracks, discoloration and contamination. 
A tablet should have the strength to withstand the rigors of mechanical 
shocks encountered in its production, packaging, shipping and dispensing. 
On the other hand, the tablet should have the chemical and physical 
stability to maintain its physical attribute over time and must be able to 
release the medicinal agent (s) in the body in a predictable and 
reproducible manner (Banker and Anderson, 1986). 
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For the tablet to achieve these properties it should contain one or more 
medicaments plus a variety of excipients and should be produced with a 
suitable method of preparation. Most of settings concerned with variables 
in tablet formulations are iterated and optimized during different levels of 
the preformulation studies. 
1.1.2.1. Preformulation studies: 
The objective of preformulation studies is to develop a portfolio of 
information about the drug substance to serve as a set of parameters against 
which detailed formulation design can be carried out. Preformulation 
investigations are designed to identify those physicochemical properties of 
drug substances and excipients that might influence the formulation 
design, method of manufacture and pharmacokinetic–biopharmaceutical 
properties of the resulting product.  
The properties are generally concerned in preformulation studies might 
include drug identity and purity, drug crystal properties and polymorphism, 
particle size, bulk powder properties, formulation moisture content and 
hygroscopicity, powder compactability and flow properties and drug 
solubility and permeability (Augsburger and Zellhofer, 2006). 
 
1.1.2.2. Drug –excipient compatibility studies:  
Acknowledging the interaction of drugs and excipients is essential in the 
initial formulation of a tablet and during processing scale-up, when 
problems arise, to determine if incompatibility exists which affects 
manufacturing or stability. Drug- excipient interactions are often directly 
related to moisture content of the ingredients or to the humidity conditions 
and can be physical interactions (melting and volatilization) and/or 
chemical ones. Tests for excipient-drug interactions are usually conducted 
on blends of the pure drug and excipients in ratios similar to those in the 
final dosage form. These studies are often performed with the help of a 
factorial or fractional–factorial experimental design. Powders are 
physically mixed and may be granulated or compacted to accelerate any 
possible interaction ( Augsburger and Zellhofer ,2006). 
 
1.1.2.3. Excipients:  
These are the additives used to convert pharmacologically active 
compounds into pharmaceutical dosage forms suitable for administration 
to patients and they constitute between 5-70% of the tablet weight. The 
behavior of the dosage form is dependant on process variables and the 
relationship between the various excipients and their impact on the active 
ingredients. 
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1.1.2.3.1. The general criteria of excipients: 
The general criteria essential for excipients are physiological inertness, 
physical and chemical stability, conformance to regulator agency 
requirements, no interference with drug bioavailability, absence of 
pathogenic microbial organisms and commercial availability at low cost 
(Chan and Chew, 2002). 
1.1.2.3.2. The roles of excipients: 
Excipients have greater and critical role in the formulation and the 
appearance of the tablet and its physical parameters like hardness, 
friability, weight variation, dosage variation, disintegration time and 
dissolution profile. Therefore excipients must add adequate flow to the 
tablet mix in the machine hopper to enable uniform fill of the dies as poor 
flow properties would result in weight variation outside acceptable limits. 
They must have sufficient cohesive properties to form a firm strong tablet 
under adequate compression force since poor quality excipients would 
result in hardness and friability problems. They must have lubrication 
property to prevent binding of the tablet and punches in the dies. Finally 
excipients must result in uniform mixing to give uniform dosage in each 
tablet and excipients must have good disintegration properties to achieve 
satisfactory release of drug after administration (Ranadive, 2004). 
1.1.2.3.3. Classification of excipients: 
 Depending on the intended main function, excipients could be 
subcategorized into different groups: 
1.1.2.3.3.1. Fillers or diluents:  
Materials are used to produce tablets of a reasonable size by diluting the 
small amounts of the drug with an inert material(s). Both organic and 
inorganic materials are used as filler e.g lactose, sugar and modified 
dextrin, calcium carbonate and sodium chloride, sugars and sugars alcohol 
sorbitol, sucrose and mannitol (Rumbic and Kottke, 1996). 
1.1.2.3.3.2. Binders and adhesives:  
These are used to promote cohesive compact and are much more effective 
when added as solution in the preparation of the granulations than when 
added dry to a direct or double compression formula. E.g. natural gums 
such as acacia and tragacanth, modified natural polymers such as the 
alginates and cellulose derivatives, natural protein such as gelatin. Starch 
paste has historically been one of the most common granulating agents 
(Banker and Anderson, 1986). 
1.1.2.3.3.3. Disintegrants: 
Disintegrant is a material added to most tablet formulations to overcome 
the cohesive strength introduced into the mass by compression and to 
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facilitate a break up or disintegration of the tablet when it contacts water in 
gastrointestinal tract. It may function by drawing water into the tablet; 
swelling and causing the tablet to burst a part, destroying the binder by 
enzymatic action or producing gas normally carbon dioxide in contact with 
water. E.g. starch and its derivatives, clays and bentonite and modified 
polymers. All disintegrants are hygroscopic and draw liquid into the tablet. 
Super disintegrants are classified into modified cellulose SCMC, cross 
linked polyvinylpyrollidone crospovidone, modified starch and sodium 
starch glycolate ( Rumbic and Kottke, 1996 ).  
1.1.2.3.3.4. Lubricants, antiadherents and glidants : 
These materials are typically described together because they have 
overlapping functions. Lubricants are intended to reduce the friction during 
tablet ejection between the walls of the die cavity in which the tablet is 
formed. Antiadherents have the purpose of reducing sticking or adhesion 
of any tablet granulation or powder to the faces of the punches or to the die 
wall. Glidants are intended to promote flow of the tablet granulation or 
powder materials by reducing friction between the particles. 
Metalic stearates (magnesium and calcium), colloidal silicas and talc are 
materials that, primarily described as antiadherents, are typically also 
lubricants with some glidants properties as well. The most effective true 
lubricants are hydrophobic; very small quantities are often used (1% or less 
of the formulation) because too much lubricant can waterproof the tablet, 
which can hinder its disintegration, dissolution and/or bioavailability. 
Alkaline metal stearates are incompatible with some drugs (e.g. Aspirin 
and ascorbic acid) (Jackson, Young and Pant, 2000). 
Laminar Lubricants are mixing sensitive. Water soluble Lubricants are not 
nearly as effective as the hydrophobic lubricants and are used when a tablet 
must be completely water soluble (e.g. effervescent tablets) (Banker and 
Anderson, 1986). 
1.1.2.3.3.5. Colorants, flavors and sweeteners: 
Colors and dyes are used to facilitate product identification and production 
of more elegant product. The two forms of colors are typically been used in 
tablet preparation are the (Food, Drug and Cosmetic) and (Drug and 
Cosmetic) dyes. 
 Flavors and flavor modifiers are used to improve the taste and aroma of 
foods and pharmaceuticals. Different flavor concentrations produce highly 
subjective sensations. The selection of a suitable flavor system is 
dependent on the properties of the drug substance and the physical form of 
the finished product like product texture (e.g. viscosity of formulation, 
solid or liquid). Water content, taste of the subject drug and vehicle 
 6
components within which the drug is presented have a significant bearing 
on the performance of the flavor system ( Reiland and Lipari, 2006).The 
criteria used to select flavors during formulation are immediate flavor 
identity from the formulation as it is ingested, compatible mouth feel 
factors and rapid development of a fully blended flavor in the mouth 
during ingestion of the product, absence of off  notes in the mouth and a 
mild transient aftertaste during ingestion of the product. The selection of a 
flavor system, thus, requires an extensive evaluation of a number of 
organoleptic qualities. Flavors are usually limited to chewable tablets or 
other tablets intended to dissolve in mouth ( Reiland and Lipari, 2006). 
The use of sweeteners is primarily limited to chewable tablets to exclude or 
limit the use of sugar in tablets (e.g. mannitol, saccharin, aspartame) 
(Banker and Anderson, 1986). 
 
1.1.2.3.4. Drug- excipient interaction: 
Though excipients can act as stabilizers, it is fair to state that they can 
adversely affect drug quality. Drug degradation with the loss of efficacy 
may be caused by chemical interaction between functional groups in 
excipient, and those associated with the drug. Aldehyde groups in 
excipients can react with primary, secondary or tertiary amino groups in 
the drug molecule (Chan and Chew, 2002). 
 Physical interactions between drug and excipient also compromise quality. 
Adsorption of drug by microcrystalline cellulose results in drug dissolution 
being less than complete. Interaction between chloramphenicol stearate 
and colloidal silica during grinding led to polymorphic transformation 
(Chan and Chew, 2002). 
Excipients may indirectly interact with active ingredients by altering pH or 
ionic strength and accelerating hydrolytic reactions in liquid presentation. 
Microcrystalline cellulose is a partially deploymerized Cellulose that is 
partial-crystalline/part non-crystalline and hygroscopic. Adsorbed water is 
not held in any bound state but is rapidly equilibrated with the environment 
during processing or storage. Thus, it is possible that in a dosage form, 
water can be sequestrated by a more hygroscopic active ingredient. If the 
drug is moisture sensitive (aspirin), degradation may follow (Chan and 
Chew, 2002).  
The concentration of magnesium stearate and time of mixtures lubrication 
can affect the content uniformity of active ingredients in mixtures that are 
based on particle interactions (Swaminathan and Kildsig, 2002). 
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1.1.2.3.5. Choice of excipients:   
Excipient choice in solid dosage forms depends on several factors: 
a) Physicochemical properties of drug: Polymorphic forms hydrate, 
heat/ moisture sensitive, poorly soluble, poorly absorbable and poor 
stability in vivo; b) Physicochemical properties of excipients: 
Physically stable polymorphic forms hydrates, hygroscopic, chemically 
stable, compatible with drug and rheology flow; c) Manufacturing 
process requirement: Direct compression, wet granulation, fluid bed 
granulation/coating, spray drying and other novel processes; d) 
Delivered dose of drug: High dose and low dose; e) Route of 
administration: oral, pulmonary, transdermal, buccal, rectal and vaginal; 
f) Desired release characteristics: immediate release, sustained release 
and modified release (Joshi and Duriez, 2005). 
 
1.1.3. Tablet production : 
 
Based on the preformulation information, decisions can be made regarding 
formulation design and process strategy of tablets manufacturing methods. 
All tablets are made by compressing a particulate solid between two 
punches in a die of a tablet press. For an active ingredient to be 
transformed into tablets of satisfactory quality, the formulation must have 
three essential attributes. First, the formulation must flow into the die space 
of the tablet press sufficiently rapidly and in a reproducible manner. 
Otherwise, unacceptable variation in tablet weight and content of active 
ingredient will ensue. Second, the particles in the formulation must cohere 
when subjected to a compressing force, and that coherence should remain 
after the compressive force has been removed. Third, after the compression 
event is complete, it must be possible for the tablet to be removed from the 
press without damage to either the tablet or the press. Very few ingredients 
possess all three of these essentials and some possess none of them. Hence 
some preliminary treatment is almost invariably necessary (Armstrong, 
2002). 
In general tablets can be manufactured by two methods, direct compression 
or granulation method. Initial guidance may be provided by the proposed 
dose, relatively low dosage drugs often are tableted by direct compression 
and large doses of poorly compactable drugs may be granulated prior to 
tabletting, other factors are compactability and stability characteristics of 
the drug ( Augsburger and Zellhofer, 2006). 
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1.1.3.1. Direct compression: 
Direct compression is the process by which tablets are compressed directly 
from the blends of the active ingredient and suitable excipients. 
 
1.1.3.2. Granulation:  
  
Granulation is a process of size enlargement and it serves several purposes 
in the tablet manufacturing process.  It improves flow by increasing 
particle size since large particle flow more readily than small ones, 
improves compression characteristics, adding to the cohesive strength of 
the tablet, once a homogenous mixture has been achieved segregation is 
prevented, since particles that are stuck together can not separate. 
Granulation reduces dust and improve solution or disperation rate. 
There are two basic methods of granulation, wet and dry methods .the wet 
method is the older more traditional method and the dry method is the one 
with certain advantages that often make it the method of choice to day 
(The Fitzpatrick, 1997)(Augsburger and Zellhofer ,2006). 
1.1.3.2.1. Wet granulation: 
This is a method by which particles of active ingredient with diluents are 
struck together using an adhesive usually being water based. The result is 
granular product which flows more readily and has an improved ability to 
cohere during compression. Despite its complexity and inherent 
disadvantages, even now about half the tablet produced world wide are 
manufactured by this process.  
1.1.3.2.2. Dry granulation: 
 It is an alternative method that can be used, and in this process the 
components of the formulation are compressed in the dry state. If sufficient 
bonding strength can not be achieved by compression alone, a binder is 
added, also in the dry state. The initial compression stage can take place by 
one of two methods. The first uses conventional tablet press, a process 
often referred to as slugging because the components of the formulation 
will not have the necessary attributes for producing good tablets. The tablet 
produced at this stage (the slugs) will not of acceptable quality, especially 
with regard to appearance and weight uniformity. The slugs are then 
broken down to form a granular product which after sieving can then be 
compressed again to give satisfactory tablets. Slugging at high pressure 
should be avoided because it was found that the ease of the compressibility 
of the formulation at the second compression was inversely proportional to 
the pressure used at the slugging stage. A second method of compression is 
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roller compaction which is the consolidation of particles by exerting a 
mechanical pressure on two compacting rolls to produce a densified sheet 
of product. The resulting compact is comminuted to the required particle 
size with the use of a mill (The Fitzpatrick, 1997). 
 
1.1.3.3. Unit operations: 
Regardless of whether tablets are made by direct compression or 
granulation, the first steps, milling and mixing are the same and the 
subsequent steps are different. Typical unit operations involved in wet, dry 
granulation and direct compression are as follow: 
Wet granulation: milling and mixing of the drugs and excipients→ 
preparation of binder solution→ wet massing of binder solution or 
granulating solvents→ screening of wet mass→ drying of the wet mass→ 
blending with lubricants and disintegrant to reduce running powder→ 
compression of tablets. 
Dry granulation: milling and mixing of the drugs and excipients→ 
compression into slugs or roller compaction → milling and screening of 
slugs and compacted powder → mixing with lubricants and disintegrant → 
compression of tablets. 
Direct compression: milling and mixing of the drugs and excipients→ 
compression of tablets (Augsburger and Zellhofer, 2006). 
 
1.1.4. Tablet Evaluation: 
To establish the quality of a tablet product and to ascertain that the product 
delivers the intended active ingredient in an accurate and reproducible 
manner, the tablet testing should be broadly divided into three aspects or 
categories: 
a. Confirmation of the nature of the active ingredient and the product 
(identity, quantity, impurities and integrity). 
b. Establishing pharmaceutical availability of the active moiety both in 
      vitro and in vivo in humans and, if required, in animals. 
c. Establishing stability profiles to achieve shelf life (Qureshi, 2002).
  
Evaluation should include both raw materials and finished dosage form. 
Raw materials identification includes qualitative determination, 
measurement of particle size distribution, polymorphism and racemization, 
moisture content…etc. 
For tablet dosage form, chemical and physical evaluation must be made 
with bioavailability property to monitor tablet production quality. 
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The control of general appearance of a tablet involves the measurement      
of a number of attributes such as a tablet size, shape, color, presence or 
absence of an odor, taste, surface, texture physical flows and consistency 
and legibility of any identification markings. 
 
1.1.4.1. Physicochemical quality control of tablets: These include:  
I. Tablets require a certain amount of strength or hardness and resistance to 
friability to withstand mechanical shocks of handling in manufacture, 
packaging and shipping. More recently, the relationship of hardness to 
tablet disintegration, and perhaps more significantly to the drug dissolution 
release rate has become apparent (Qureshi, 2002). 
II. To evaluate a tablet’s potential for efficacy, the amount of drug per 
tablet needs to be monitored and a measure of the tablet’s ability to release 
the drug needs to be ascertained. Accordingly uniformity of a dosage unit, 
disintegration, dissolution and impurities tests should be carried (Qureshi, 
2002). 
 
1.1.4.1.1 Hardness and friability: 
Hardness (crushing strength) has been defined as the force required to 
break a tablet in a diametric compression test. It is like thickness of tablet 
is a function of the die fill and compression force. At a constant die fill, the 
hardness values increase and thickness decreases as additional compression 
force is applied, this relationship holds up to a maximum value for 
hardness and minimum value for thickness beyond which increases in 
pressure cause the tablet to laminate or cap, thus destroying the integrity of 
the tablet(BP2000). Although the hardness of a tablet gives some 
indication of its mechanical robustness, it doesn’t truly measure the ability 
of the tablet to withstand the handling during processing and shipping. 
Friability test is designed to assess the resistance of the surface regions to 
abrasion or other forms of general wear and tear in form of a percentage 
loss in weight (BP2000)(Qureshi, 2002). 
 
1.1.4.1.2. Uniformity of dosage units:  
It is conducted to establish consistency in the content of active ingredients 
from tablet to tablet. There are generally two approaches taken in 
establishing this weight variation and content uniformity. 
If the active ingredient represents not less than 50% weight of the tablet 
and greater than 50 mg, then one may establish uniformity of dosage units 
using the weight variation method. A sample of 10 tablets is weighed 
individually and results of these weighing are recorded (Qureshi, 2002). 
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In the case of content uniformity approach, samples of 10 tablets are 
individually analyzed using the analytical method described under the 
assay procedure. It is mandatory to use content uniformity for tablets with 
less than 50 mg of active ingredient and/or representing less than 50% total 
mass of the tablets. It is preferred over the weight variation approach as it 
more precisely reflects the variation of the active ingredient from tablet to 
tablet. The required specification for this test is that uniformity of dosage 
unit should be within a range of 85 – 115% with a relative standard 
deviation of less than or equal 6% (BP2000, USP2004).  
Content uniformity is an important product quality attribute that provides 
the patient assurance that no matter which tablet or capsule is taken, an 
acceptable amount of active drug will be delivered. Manufacturers perform 
validation to demonstrate that the mixing and finishing operations produce 
uniform dosage units with respect to the content of active ingredient. 
Where applicable, batches are tested for content uniformity prior to release 
to provide assurance that the product will comply with compendial 
standards of uniformity (Qureshi, 2002). 
 
1.1.4.1.3. Test for Impurities: 
The impurities present in a tablet product may fall under different 
categories such as: foreign substances that are introduced by contamination 
or adulteration; toxic impurities that have significant undesirable biological 
activity, even as a minor component, and require individual identification 
and quantization by specific tests; concomitant components that are 
characteristic of many bulk pharmaceutical preparation but are not 
considered as impurities, for example (optical and geometrical isomers) 
and ordinary impurities are those that are innocuous by virtue of having no 
significant biological activity in the amount present. These impurities may 
arise out of the synthesis, preparation and/or degradation of the product. 
Generally most of the impurity profile is established from bulk 
pharmaceutical material (raw material). However, from the finished 
product perspective products are only analyzed to the extent of toxic 
impurities. In this case, usually it must be established that a product is 
either free from the specific impurities or the impurities are within the 
acceptable specifications (Rhodes and Morisseau, 2002) (BP2000). 
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1.1.4.1.4. Disintegration test:  
It is a test to establish how fast a tablet disintegrates into aggregates and/or 
fine particles. The test assumes that if a product disintegrates within a short 
period of time, such as within 5 min, then the drug would be released as 
expected and one should not anticipate problem in the quality of a drug 
product. The test is conducted using a specially designed instrument 
known as disintegration apparatus with selected pharmacopeial 
specification. The disintegration time may be markedly affected by the 
amount of disintegrant used as well as the tablet process condition like 
compressional force (BP2000). 
 
1.1.4.1.5. Dissolution test:   
It is the most important way to study, under in vitro conditions, the release 
of a drug from a tablet, and thus represents an important tool to assess 
factors that affect the bioavailability of a drug from a tablet dosage form. It 
is an evaluation as to whether or not a tablet releases its drug contents 
when placed in the environment of the gastrointestinal tract. The rate of 
dissolution may thus be directly related to the efficacy of the tablet product 
as well as to bioavailability differences between formulations .The test is 
conducted using a specially designed instrument known as dissolution 
apparatus with selected pharmacopeial specification (BP2000). 
 
1.1.5. Tablet packaging system: 
Pharmaceutical packaging is that combination of components necessary to 
contain, preserve, protect and deliver a safe efficacious drug product. 
Packaging material in the pharmaceutical industry is selected adequately to 
preserve the integrity of the product .The material selected must have the 
following characteristic,  must protect the preparation from environmental 
conditions, must not be reactive with the product, not impart to the product 
tastes or odors, must be nontoxic, be FDA approved, must meet applicable 
tamper resistance requirements and must be adaptable to commonly 
employed high speed packaging equipment(Banker and Anderson, 1986). 
Types of packing materials used are, glass ( colored glass, light protection, 
type I, borosilicate glass, type II, treated soda-lime glass, type III, regular 
soda-lime glass, and type NP-General purpose soda-lime glass),plastic( 
polystyrene, nylon, polycarbonate, acrylic multipolymers, polyethylene, 
terephthalate and other plastics material) and metal in collapsible tube (tin, 
aluminum, lead and linings (wax linings). 
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1.1.5.1. Multi dose tablet dosage forms packaging:  
The packaging usually consist of a glass or plastic bottle with a closure that 
might range from a plastic – lined metal screw cap to unlined plastic cap. 
Color of the container will depend on the specific properties of the drug. 
The glass type commonly used is NP, a soda lime glass for non-parenteral 
products. The common color, when used, is amber. The plastic type 
commonly used is high density polyethylene (HDPE).The USP/NF 
provides the test for characterizing the degree of light transmission for 
glass bottle. For plastic bottle three tests should be carried, chemical, 
spectral and moisture barrier tests. 
In addition to the USP/NF criteria, choice of bottle size, expressed as 
overflow volume is one more parameter that must be specified for the 
package system. The remaining headspace volume is then filled with a 
pharmaceutical coil material which can be chosen from cotton, rayon and 
polyester according to drug product properties. Another component that 
may be added to a bottled product is a desiccant formed from calcium 
chloride or silica gel. The final packaging component to consider for multi 
dose tablet dosage forms is the closure. Typically the closure is a threaded 
screw – on type made of metal such as tinplate, or of plastic such as 
polypropylene, HDPE, or LDPE. More important than closure material is 
the liner which is made to aid in the formulation of a hermetic seal between 
the cap and the bottle. The liner is usually a multilayer structure consisting 
of a pulp or paper board backing, a foil layer or an inner layer of an 
acceptable plastic such as LDPE or PVC for a high moisture barrier 
(Banker and Anderson, 1986). 
1.1.5.2. Unit dose packaging of tablet dosage forms: 
 It has become very popular because of the convenience to the pharmacist, 
physician and the patient. There are two major classes of unit dosage 
packaging that are commonly used today blister packaging and strip 
packaging. 
 
1.1.5.2.1. The blister packaging mode:  
It has been extensively used for pharmaceutical packaging for several good 
reasons: it provides excellent environmental protection, coupled with an 
esthetically pleasing and efficacious appearance, provides user 
functionality in terms of convenience, child resistance and tamper 
resistance.  
The blister package is formed by heat – softening a sheet of thermoplastic 
resin and vacuum – drawing the softened sheet of plastic into a contoured 
mold. After cooling, the sheet is released from the mold and proceeds to 
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the filling station of the packaging machine. The semi–rigid blister 
previously formed is filled with product and lidded with a heat–sealable 
backing material.  
The backing material or lidding can be of either a push – through or 
peelable type. For a push – through type of blister, the backing material is 
usually heat – seal – coated aluminum foil. The coating on the foil must be 
compatible with the blister material to ensure satisfactory sealing both for 
product protection and for tamper resistance. Peelable backing materials 
have been used to meet the requirements of child resistance packaging. 
This type of backing must have a degree of puncture resistance to prevent a 
child from pushing the product through the lidding and must also have 
sufficient tensile strength to allow the lidding to be pulled away from the 
blister even when the lidding is strongly adhered to it. To accomplish this, 
a material such as polyester or paper is used as a component of the backing 
lamination. Foil and metallized polyester are used as component of 
backing lamination. Materials commonly used for the thermo formable 
blister are polyvinyl chloride (PVC), PVC/Polyethylene combinations, 
polystyrene and polypropylene (Banker and Anderson, 1986).  
For commercial reasons and because of certain machine performance 
characteristic, the blisters on most unit dose packaging are made of 
polyvinyl chloride. For added moisture protection, polyvinylidene chloride 
(Saran) or polychlorotrifluoro ethylene (Aclar) films may be laminated to 
PVC. A blister formed of PVC is significantly more permeable than the 
material sheet form. Blister material can be fabricated with amber dyes to 
create a light – absorbent material for light protection. 
 
1.1.5.2.2. Strip package mode:  
It is a form of unit dose packaging that is commonly used for the 
packaging of tablets and capsules. A strip package is formed by feeding 
two webs of a heat–sealable flexible film through either a heated crimping 
roller or a heated reciprocating platen, then product is dropped into the 
pocket formed prior to forming the final set of seals. A continuous strip of 
packets is formed, generally several packets wide depending on the 
packing machine’s limitation. The strip packets are cut to the desired 
number of packets in length. The product sealed between the two sheets of 
film usually has a seal around each tablet, with perforations usually 
separating adjacent packets. The seals can be in a sample rectangular or 
(picture–frame) format or can be contoured to the shape of the product. 
Since the sealing is usually accomplished between pressure rollers; a high 
degree of seal integrity is possible. The use of high barrier materials such 
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as foil laminations or Saran – coated films, in conjunction with the 
excellent seal formation, makes this packaging mode appropriate for the 
packaging of moisture sensitive products (Banker and Anderson, 1986). 
A number of different packaging materials are used for strip packaging for 
high–barrier applications; a paper/polyethylene/foil/polyethylene        
lamination is commonly used. When product visibility is important, heat 
sealable cellophane or heat sealable polyester can be used. Also, the front 
and back of the package may be used in dissimilar materials. The choice of 
material used depends on both product and equipment requirements. 
(Banker and Anderson, 1986) 
 
1.2. Effervescent tablets 
Effervescence form has proved its utility as an oral delivery system in the 
pharmaceutical and dietary industries for decades. In Europe, effervescent 
dosage forms are widely spread, and their use is growing in the U.S. 
Effervescent tablet is a tablet intended to be dissolved in water before 
administration. It contains, in addition to the active ingredient(s), mixtures 
of acids (e.g. citric acid, tartaric acid) and bases (e.g. sodium bicarbonate), 
which release carbon dioxide when dissolved in water (Avani, 2006). 
1.2.1. Reasons for effervescent tablets: 
Reasons to formulate some active ingredients in form of effervescent 
tablets include, those disruptive to the stomach by producing gas during 
dissolution (optimal compatibility), those that are pH sensitive, those 
requiring a large dose, better and quicker absorption and advantages in 
case of swallowing problems (Avani, 2006). 
 
1.2.2. Formulation of effervescent tablets: 
With regards to compressibility and compactability, properties of raw 
materials in effervescent product are similar to conventional tablet. 
However, poor compactability can not usually be compensated for by the 
use of binders as this will prevent rapid dissolution of effervescent tablets. 
Binders are normally necessary in effervescent tablets to bring the tablet 
hardness to a point where handling is possible. These binders should be 
water soluble and include dextrose, sorbitol, xylitol and lactose. A binder 
should be used very cautiously because it can carry free moisture into the 
tablet, which is undesirable and can increase disintegration times when 
used in large quantities. The ideal amount of binder is one that makes the 
tablet hard enough to handle, but soft enough to disintegrate (the harder the 
tablet, the slower the disintegration) and dry enough to be stable. 
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Lubrication of effervescent tablets has historically been the main stumbling 
block to an acceptable, marketable product. Typical lubricants such as 
magnesium stearate are not useful due to their insolubility in water. Most 
formulators have to use water–soluble lubricants such as sodium benzoate, 
polyethylene glycol and adipic acid. These are minimally effective, and 
depend heavily on the type of granulation they are used in. There are tablet 
presses that use lubrication spray on the punches so that the formula 
doesn’t require lubrications (Stahl, 2006). 
Depending on the product, formulators can use color (artificial or natural), 
sweeteners (acesulfame potassium, sodium saccharin, aspartame and 
surcalose) and flavors (artificial or natural) to enhance a product or to mask 
off–notes derived from the active ingredients. 
 Materials used for effervescent products should have the following 
properties: the adsorption/desorption isotherm, low moisture content (to 
avoid a premature effervescent reaction), the aqueous solubility, easy 
wetting and good taste. 
1.2.2.1. Acids used in effervescent tablet formulation: 
The acidity for the effervescent tablet can be obtained from three main 
sources: acids, acid anhydrides and acid salts. 
Traditional source of acid materials are organic acids (citric and tartaric 
acid), some acid salts are used. 
Citric acid: is obtained as monohydrate or anhydrate. A variety of particle 
size grades are available, colorless translucent crystals, or white, granular 
to crystalline powder. It is odorless and has a strong acidic taste, soluble in 
less than one part of water and 1 in 1.5 parts of ethanol. 
Citric acid monohydrate melts at 100Cº, loses water at 75Cº, and becomes 
anhydrous at 135Cº, fuses at 153Cº and at relative humidities (RH) lower 
than approximately 65% it effloresces at 25Cº. The anhydrous acid is 
formed at humidities below approximately 40%. At RH between 
approximately 65 and 75% it sorbs insignificants amount of moisture but 
above this, substantial amounts are absorbed (Kibbe, 2000), (Lindberg 
and Hansson, 2002). 
Tartaric acid: occurs as colorless monoclinic crystals or white or almost 
white crystalline powder with an extremely tart taste,  soluble 1 in 0.75 
parts of water, and 1 in 2.5 parts of alcohol, sorbs insignificant amount of 
moisture at RH up to approximately 65% but at RH above approximately 
75% substantial amount are absorbed. Studies indicate that tartaric acid 
behaves in a manner similar to that of anhydrous citric acid .During 
compression, the acid fragments predominantly, and elastic deformation 
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and consequently the elastic recovery were low (Kibbe, 2000) (Lindberg 
and Hansson, 2002). 
Ascorbic Acid: Occurs as white to light yellow crystalline powder or 
colorless crystals with a sharp acidic taste, odorless, not hygroscopic, upon 
exposure to light it gradually darkens and soluble 1 in 3.5 parts of water 
and 1 in 50 parts of ethanol. Its particles show intermediate fragmentation 
during compaction. The relatively low tablet strength indicates that the 
attraction forces are relatively weak and not very resistant to stress, 
relaxation and elastic recovery. A comparison of the formation of carbon 
dioxide from effervescent tablets based on anhydrous citric acid, ascorbic 
acid or tartaric acid and sodium bicarbonate in stoichiometric proportions 
indicate that ascorbic acid and anhydrous citric acid behaved similarly. 
However, tartaric acid forms the most carbon dioxide, but the 
disintegration time is longer. Since ascorbic acid is less hygroscopic than 
citric and tartaric, using ascorbic acid as the only acid source make it 
possible to produce effervescent tablets in non air conditional 
area(Kibbe,2000) (Lindberg and Hansson, 2002). 
Fumaric Acid: It is a white, odorless or nearly odorless crystalline powder, 
soluble 1 in 222 parts of water and 1 in 28 parts of ethanol and is not a 
hygroscopic substance (Kibbe,2000) (Lindberg and Hansson, 2002). 
Acetyl salicylic acid (aspirin): Although it is a drug frequently used in 
effervescent form, it can not be used as the acid source because of its low 
water solubility. Additional acid is necessary to decrease the reaction time 
(Lindberg and Hansson, 2002). 
Other acids: Malic acid is hygroscopic and readily soluble in water, has a 
slight apple flavor, white or nearly white crystalline powder or granules 
having a slight odor and strongly acidic taste (Lindberg and Hansson, 
2002). 
Acid anhydrides: The use of these as the acid precursor has been 
investigated. However, their use in commercial products is limited 
(Lindberg and Hansson, 2002). 
Acid salts: Amino acid hydrochlorides readily release acid when in 
solution. However these materials have the disadvantage of being 
expensive and rather hygroscopic (Lindberg and Hansson, 2002). 
Other suggested acid sources include sodium dihydrogen citrate, which is 
non hygroscopic below approximately 93% RH and sodium acid phosphate 
which is very soluble in water (Stahl, 2006). 
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1.2.2.2. Bases used in effervescent tablet formulation: 
Both carbonates and bicarbonates are used as carbonate sources but the 
latter is most often used. Sodium bicarbonate: It is an odorless, white 
crystalline powder with a saline slightly alkaline taste. A variety of particle 
size grades of powders and granules are available, the carbon dioxide yield 
is approximately 52% by weight, at RH below approximately 80% (at 
room temperature). The moisture content is less than 1%, above 85% RH. 
It rapidly absorbs an excessive amount of water and may start to 
decompose. Solubility in water is I part in 11 parts at 20Cº, practically 
insoluble in 95% ethanol at 20Cº. It is a non elastic substance, mainly 
consolidates by plastic deformation and not by fragmentation. In order to 
overcome its poor flowbility and low compressibility, a spray–drying 
technique is used. Additives such as polyvinyl pyrrolidone and silicon oil 
were found to be essential to obtain direct compressible spray – dried 
sodium bicarbonate (Kibbe, 2000) (Lindberg and Hansson, 2002). 
Sodium carbonate: It is commercially available as anhydrous and as 
monohydrate or decahydrate. All forms are very soluble in water. The 
anhydrate is hygroscopic (Lindberg and Hansson, 2002). 
Potassium bicarbonate: It is colorless, odorless transparent prisms 
precipitate or white granular powder, very soluble in water , less sensitive 
to heat in connection with drying than is sodium bicarbonate, above 
approximately 80% RH at 20 Cº substantial amounts of water are 
absorbed(Lindberg and Hansson,2002). 
Calcium carbonate:  It occurs as fine, white, odorless and tasteless powder 
or crystals, practically insoluble in water and ethanol (95%), 
nonhygroscopic, a high density, not very compressible material and known 
to consolidate by fragmentation (Kibbe, 2000) (Lindberg and Hansson, 
2002). 
Other sources: Amino acid alkali metal carbonate derivatives, such as 
sodium glycine carbonate, have been suggested as sources of carbon 
dioxide, nonhygroscopic heat resistant, stable substances. However, the 
carbon dioxide yields – approximately 18% by weight (only about one 
third of sodium bicarbonate) (Lindberg and Hansson, 2002). 
 
1.2.3. Production of effervescent tablets: 
Effervescent tablets and powders are produced in much the same manner 
as conventional tablets and powders with special requirements. 
1.2.3.1. Production requirements: 
a) Strict control of temperature and humidity in all areas is a must (65 to 75 
Fº, relative humidity of 10 percent) or the formulation will begin a 
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chemical reaction after its packaging. In essence the tablet will self-
destruct because the by products of an effervescent reaction are water and 
carbon dioxide. 
b) All equipment should be well grounded and should allow you to     
make it completely and absolutely dry after wash – down. Any traces of 
moisture in the equipment will give erratic granulations results and most 
likely result in lost batches of product. 
c) Effervescent products normally require tablet presses that can deliver 
high compression forces. If the tablets are to be wrapped in foil or placed 
into a tube; give careful attention to the tablet parameters during 
compression. The tablet thickness should be monitored to ensure that the 
wrapping or packaging equipment can handle the tablets. 
1.2.3.2. Production via wet methods:  
Conventional wet granulations of the effervescent base can be performed 
by carefully adding 0.1-1% w/w water to the chosen blending equipment 
followed quickly by drying steps using fluid bed dryers or using vacuum 
granulators. 
Wet granulation can be used by running two separate granulation steps for 
the alkaline and the acid components with a subsequent dry blending step. 
Advantage of this method is that only conventional equipment is needed 
but the major disadvantages are the running time and cleaning aspects. A 
critical step can be the blending process and as consequence the 
homogeneity of the tablets as not all materials are bonded into one granule 
as in conventional wet granulation process(Lindberg and Hansson,2002) 
(Stahl, 2006). 
Wet granulation can also be performed by one granulate method using 
organic solvents, as the effervescent reaction only starts if the materials 
come into contact with water. The only disadvantage of this method is the 
need for more complex equipment to handle these fluids (exhaust gas 
treatment).The method offers a lot of advantages which originate from the 
lower heat of evaporation in comparison with water, a high through put, 
the possibility for drying at lower temperatures and the freedom to use a lot 
of different excipients to achieve the desired product characteristic. Use of 
water in wet granulation for the production of effervescent tablets need 
adequate control of the process vacuum processing, using a high sheer 
granulator with subsequent fluid dryer(Lindberg and  Hansson,2002) 
(Stahl,2006). 
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1.2.3.3. Production via dry methods: 
The use of dry methods like slugging roller compaction or direct 
compression in the production of effervescent tablets is attractive as no 
liquid is involved (Stahl, 2006) (Lindberg and Hansson, 2002). 
 
1.2.4. Packaging and stability of effervescent tablets: 
The best way to stabilize effervescent tablets is to produce them in an 
environment where humidity is under strict control and to package the 
tablets in a suitable moisture barrier package system. All ingredients in the 
formulation must be anhydrous. Many effervescent product failures occur 
due to inadequate packaging material. Many times the choice of packaging 
materials is made based on pricing, rather than considering stability issues 
(Lee, 2006). 
Effervescent tablets are susceptible to reacting with ambient humidity 
while still in their packaging.  Sophisticated special purpose packaging is 
employed to ensure that effervescent tablets remain intact over long self–
lives. More specifically the two types of packaging that are typically used 
are effervescent tubes and blister–packs (foil packs). Both of these 
mechanisms minimize the amount of moisture that enters the tablet area 
while sealed and in some cases, neutralize any moisture that does penetrate 
through the use of desiccant material that absorbs moisture. 
 The tube is the classic packaging for effervescent tablets which typically 
includes a cap with a desiccant fixture that absorbs any humidity that 
might enter or leak into the tube particularly when used by the consumer. 
These tubes were traditionally aluminum but have migrated towards plastic 
as this offers better performance combined with lower cost. A new bread 
of tube with desiccant built into the lining is now also emerging (Lee, 
2006). 
 Effervescent blister packs are an alternative to the tube. These are often 
made out of aluminum and protect the tablets by sealing them in a moisture 
free environment. Pinholes are common problem in foil packets. By going 
to a heavier gauge foil, the number of pinholes will be greatly reduced. The 
area within the packet should be large enough to hold the tablets without 
creating stress on the foil, yet it should also be as small as possible to 
minimize the amount of room air that can be trapped inside with the 
tablets. After the material is being pressed into effervescent tablets then the 
surface area of the material would be significantly reduced, which means 
that the moisture absorbed from the air has also been reduced. 
Consequently, this means that the dehumidification of the environmental 
air is now less critical. The advantage of blister pack is that each tablet is 
 21
individually wrapped which means that consumption of one unit does not 
expose the remaining units to the air; hence this packaging is most 
appropriate for tablets of sporadic or infrequent use (Lindberg and 
Hansson, 2002) (Stahl, 2006) (Lee, 2006). 
 
1.3. Chewable tablets 
Chewable tablets are designed to be broken down rapidly in the buccal 
cavity by the action of teeth and are not intended to be swallowed intact. 
The purpose of chewable tablets is to provide a unit dosage form of 
medication which can be easily administered to infants and children or to 
the elderly who may have difficulty to swallow a tablet intact. 
1.3.1. Formulation of chewable tablets: 
The chewable tablet dosage form consists of the active ingredients with 
different types of excipients (diluents, binders, lubricants, flavors …..etc). 
No need for disintegrants. 
Mannitol is the diluent of choice due to its negative heat of solution which 
produces a cooling sensation in the mouth and acts as an effective mask for 
unpleasant tastes. Mannitol is D–mannitol, it is a hexahydrix alcohol 
related to mannose and is isomeric with sorbitol. It occurs as white, 
odorless crystalline powder (cohesive powder) or free flowing granules. It 
has a sweet taste approximately as sweet as glucose and half as sweet as 
sucrose, non hygroscopic, soluble 1 in 5.5 parts of water and 1 in 83 parts 
of ethanol. Studies show that spray–dried mannitol powder has improved 
compaction behavior compared to the granular mannitol. Spray – dried 
mannitol yields a relatively porous powder which enables faster 
penetration of water and faster disintegration. A statically significant (P< 
0.005) increase was seen in post compaction hardness upon storage. Post 
compaction hardness is independent of packing materials. DC–mannitol 
grades are available for the manufacture of chewable tablets. Mannitol is 
stable in the dry state and in aqueous solutions (Nuguru, 1999) (Joshi and 
Duriez, 2004). 
Sorbitol is also used as a diluent in chewable tablet. It is D–glucitol, 
hexahydric alcohol related to mannose and is isomeric with mannitol; 
occurs as an odorless, white or almost colorless, crystalline, available in a 
wide range of grades and polymorphic forms such as granules, flakes, or 
pellets which tend to cake less than the powdered form and have more 
desirable compression characteristic. It has a pleasant cooling, sweet taste 
and has approximately 50 – 60% of the sweetness of sucrose, soluble 1 in 
0.5 parts of water and 1 in 25 parts of ethanol. Sorbitol is a very 
hygroscopic powder and relative humidities greater than 60% at 25 Cº 
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should be avoided when it is added to direct compression tablet formulas. 
It is stable in air in the absence of catalysts and in cold, dilute acids and 
alkalis (Kibbe, 2000). 
Binders are normally necessary in chewable tablet to bring the tablet 
hardness to a point where handling is possible. Povidone or polyvinyl 
pyrrolidone (PVP) is an example of binder used. It is a fine, white to 
creamy–white colored, odorless or almost odorless, very hygroscopic, 
significant amounts of moisture being absorbed in at low relative 
humidities, freely soluble in acids, chloroform, ethanol, ketones, methanol 
and water practically insoluble in ether, hydrocarbons and mineral 
oils(Kibbe, 2000). 
Starch can also be used as a binder in chewable tablets. It occurs as an 
odorless and tasteless, fine, white–colored powder–comprised of very 
small spherical or ovoid granules whose size and shape are characteristic 
for each botanical variety (maize, potato, rice, tpioca, corn and wheat 
starch). All starches are hygroscopic and rapidly absorb atmospheric 
moisture. Approximately equilibrium moisture content values at 50% RH 
ranged from 11 to 18% of different starches. It is practically insoluble in 
cold ethanol (95%) and cold water, swells instantaneously in water by 
about 5 – 10% at 37 Cº. Polyvalent cations produce more swelling than 
monovalent ions, but pH has little effect (Kibbe, 2000). 
 Starch has been subjected to different physical and chemical modifications 
to improve its properties as a common pharmaceutical excipient. Starch 
1500 has a lower propensity for moisture than other (croscarmellose 
sodium, sodium starch glycolate) and does not rely solely on water uptake 
and swelling as mechanism for disintegration. Some data suggest that 
starch 1500 may inhibit water activity within the formulation and retard 
moisture interaction with moisture sensitive drugs like aspirin. Dry 
unheated starch is stable if protected from high humidity (Cunningham 
and Scattergood, 2001). 
Other additives might include lubricant (talc), sweetener (saccharin 
sodium) and flavoring agent (dry orange flavor).  
 
1.3.2. Production of chewable tablets: 
Chewable tablets can be formulated by the methods used for production of 
conventional tablets, direct compression, dry granulation or wet 
granulation method. 
1.3.3. Packaging of chewable tablets: 
Chewable tablets are packed in the same packaging systems of 
conventional tablets.  
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1.4. Experimental design and formulation development  
A factorial experiment is one in which the effects of more than one factor 
are investigated simultaneously in all their possible combinations. The 
simplest factorial experiment involves two factors each set at two levels 
written as 2². Such an experiment may, for example, be one in which the 
effects of two factors (filler type and filler loading level) on tablet hardness 
in chewable tablets formulation, is studied at two level (mannitol and 10% 
labeled -1) and (sorbitol and 25% labeled +1) (Alain, 1998). There will, 
therefore, be four experimental runs. When every setting of every factor 
appears with every setting of every other factor, it is termed as full factorial 
design. Full factorial designs is not recommended for 5 or more factors 
since the design under such condition requires a large number of runs and 
is not very efficient (Myers, 1990). 
1.4.1. Full factorial screening design. 
Two and three–level designs are useful for investigating of the main effects 
and to some extent the quadratic interaction effects and they are written as 
a 2ⁿ and 3ⁿ factorial design respectively. It means that n factors are 
considered, each at two or three levels. These are usually referred to as low 
and high levels in case of two-level designs and low, moderate and high 
levels incase of three-level designs. These levels numerically expressed as 
-1, 0 and +1(Myers, 1990).   
1.4.2. Formulation optimization. 
Optimization of a formulation or process is finding the best possible 
composition or operating conditions. Determining such a composition or 
set of conditions is an enormous task, probably impossible, certainly 
unnecessary, and in practice, optimization may be considered as the search 
for a result that is satisfactory and at the same time the best possible within 
a limited field of search. Thus, the type and components of a formulation 
may be selected, according to previous experience, by expert knowledge 
(possibly using an expert system), or by systematic screening. Then the 
relative and/or total proportions of the excipients are varied to obtain the 
best endpoint, or a process is chosen, and a study is carried out to 
determine the best operating conditions to obtain the desired formulation 
properties. Both of these are optimization studies (Lewis, 1999). 
 
1.5. Stability: 
The stability of a product relates to its resistance to the various chemical, 
physical and microbial reactions that may change the original properties of 
the preparation during transport, storage and use. Other criteria of stability 
are the effects of such changes on the fitness of the product for use as 
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medicine. Stability is often expressed in quantitative terms as shelf life. 
The shelf life of a medicinal product kept in its closed container under 
specified conditions is commonly defined as the time for manufacture or 
preparation until the original potency or content of active constituent has 
been reduced by 10%. 
 
1.5.1. Types of stability: There are five general types of stability defined 
by the USP, these are: a) Chemical stability: each active ingredient retains 
its chemical integrity and labeled potency within the specified limits, b) 
Physical stability: the original physical properties, including appearance, 
palatability, uniformity, dissolution and suspendability are retained, c) 
Microbiological stability: sterility or resistance to microbial growth is 
retained according to the specified requirements. Antimicrobial agents that 
are present retain effectiveness within the specified limits, d) Therapeutic 
stability: the therapeutic effect remains unchanged, and e) Toxicological 
stability: no significant increase in toxicity occurs (Allen, 2004). 
Compounding pharmacists are interested in all five types of stability but 
the compounding process emphasizes observations that can be done related 
to the chemical, physical and microbiological stabilities. 
Chemical and physical stability are important for selecting storage 
conditions (temperature, light, humidity), selecting the proper container for 
dispensing and for anticipating interactions when mixing drugs and dosage 
forms. Stability and expiration dating/beyond use–dating are based on 
reaction kinetics, i.e. the study of the rate of chemical change and the way 
this rate is influenced by conditions of concentration of reactants, products 
and other chemical species that may be present and by factors such as 
solvent, pressure and temperature(Allen, 2004). 
 
1.5.2. Mechanism of degradation: 
Chemically, the most frequently encountered destructive processes include 
hydrolysis and oxidation. 
1.5.2.1. Hydrolysis: It is solvolytic process in which drugs react with 
water to yield breakdown products having different chemical composition. 
For examples a molecule of aspirin combines with water molecule and 
hydrolyzes into one molecule of salicylic acid and one molecule of acetic 
acid.  The process of hydrolysis probably is the most important single 
cause of drug decomposition because many drugs are esters or contain 
such other groupings as substituted amides, lactones, and lactams which 
are susceptible to the hydrolytic process (Allen, 2004). 
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1.5.2.2. Oxidation: It is another destructive process to many drugs types 
including aldehydes, alcohol, phenols, sugar, alkaloids and unsaturated fats 
and oils. Chemically, oxidation involves the loss of electrons from an atom 
or a molecule. Each electron lost is accepted by some other atoms or 
molecules, causing the reaction of the recipient molecule. In inorganic 
chemistry oxidation is accompanied by an increase in the positive valence 
of an element for example ferrous+2 oxidizing to ferric+3. In organic 
chemistry, oxidation is frequently considered synonymous with the loss of 
hydrogen (dehydrogenation) from a molecule.  
The oxidative process frequently involves free chemical radicals which are 
molecules or atoms containing one or more unpaired electrons, as 
molecular atmospheric oxygen and free hydroxyl. These radicals tend to 
take electrons from other chemicals thereby oxidizing the donor. Many of 
the oxidative changes in pharmaceutical preparations are autoxidations 
which occur spontaneously under the initial influence of atmospheric 
oxygen and proceed slowly at first and then more rapidly as the process 
continues. It is a type of chain reaction beginning with the union of oxygen 
with a drug molecule and continuing with a free radical of this oxidized 
molecule participating in the destruction of other drug molecules (Allen, 
2004). 
1.5.2.3. Other destructive processes : In pharmaceutical compounding 
steps should be taken to reduce or prevent the occurrence of drug substance 
deterioration due to hydrolysis, oxidation or other processes such as 
isomerization, racemization, epimerization, polymerization, photochemical 
reactions, radiation induced reactions, decarboxylation and absorption of 
carbon dioxide(Allen, 2004) . 
 
1.5.3. Factors affecting stability: 
 The stability of a drug and its dosage form is affected by a number of 
various factors including pH, temperature, solvent, light, air (oxygen, 
carbon dioxide and moisture), humidity, particle size and ionic strength 
and dielectric constant(Allen, 2004)(USP2004). 
1.5.4. Paths of physical instability: 
Some paths of physical instability include the formation of polymorphs, 
crystallization, vaporization and adsorption (Allen, 2004). 
1.5.4.1. Polymorphs: 
Polymorphs are different crystal forms of the same chemical compound 
and differ in their crystal energies. They may exhibit differences in such 
properties as solubility, compressibility and melting point. The occurrence 
of polymorphs can be minimized by knowing the causative factors and 
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preventing them. For example, heating and shock–cooling can cause the 
formation of polymorphs. 
1.5.4.2. Crystallization:  
Crystallization of particles in suspension can result in different particle size 
distribution of the particles. This occurs often by temperature fluctuations. 
Increasing temperature results in greater solubility (often with the smaller 
particles dissolving faster) and decreasing temperature results in some drug 
in solution crystallization out on particles that are already present. This 
cycling will decrease the proportion of smaller particles and increase the 
proportion of larger crystals present. 
1.5.4.3. Vaporization: 
The term implies loss of solvent which is increased at higher temperatures. 
With a loss of solvent or liquid the resulting concentration of the product 
will increase. This may lead to over dosage when administered. Also with 
a loss of solvent, precipitation of the drug may occur if the solubility of the 
drug in the remaining vehicle is exceeded.  
1.5.4.4. Adsorption: 
The adsorption of the drug or excipients is rather common and may lead to 
a loss of the drug available for exerting its effect. Drugs may adsorb to 
filter, container, tubing, syringes, or other materials which it contacts. This 
may be of special importance to low dose drugs. Sorption can often be 
minimized by pre-treating equipment containers with silicone and for some 
materials can be minimized by the addition of albumen or similar material 
to the vehicle prior to adding the drug. 
 
1.5.5. Stability observations: 
Observation of drug instability in pharmaceutical formulations may be 
detected in some instances by a change in the physical appearance, color, 
odor, taste or texture of the formulation whereas in other instances 
chemical changes may occur which are not self-evident and may only be 
ascertained through chemical analysis(Allen,2004).  
For enhancing the stability of the drug products, many pharmaceutical 
ingredients may be utilized in compounding a dosage form. Some of these 
may be used to achieve the desired physical and chemical characteristics or 
to enhance its appearance, odor and taste; others may be used to increase 
stability, particularly against hydrolytic and oxidative processes. In each 
instance, the added pharmaceutical ingredient must be compatible with and 
not detract from the stability of the drug substance in the particular dosage 
form prepared.  
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1.5.6. Approaches to stabilizing pharmaceutical preparations: 
There are several approaches to stabilizing pharmaceutical preparations 
and such approaches depend on the instability type, the dosage form and 
ingredients compactability.  
 I.5.6.1. Drugs deteriorate by hydrolysis: 
 These can be stabilized by elimination of water from the pharmaceutical 
system. In liquid preparations water can frequently be replaced or reduced 
in the formulation through the use of substitute liquids such as glycerin, 
propylene glycol and alcohol. In certain injectables products anhydrous 
vegetable oils may be used as the drug’s solvent to reduce the chance of 
hydrolytic decomposition.  Tablets dosage forms containing water labile 
drugs, must be protected from the humidity of the atmosphere by applying 
a water proof protective coating cover tablets or by enclosing and 
maintaining the drug in tightly closed containers (Allen, 2004).  
Storage under refrigeration is advisable for most preparations considered 
unstable due to hydrolytic causes. Together with temperature, pH is a 
major determinant in the stability of a drug prone to hydrolytic 
decomposition. The hydrolysis of most drugs is dependent upon the 
relative concentrations of hydroxyl and hydronium ions and the pH at 
which each drug is optimally stable can be easily determined. For most 
hydrolysable drugs the pH of optimum stability is on the acid side, some 
where between pH 5 and 6. Therefore through judicious use of buffering 
agents, the stability of otherwise unstable compounds can be increased. 
 
1.5.6.2. Drugs deteriorate by oxidation: 
These can be stabilized by using antioxidants and by elimination of trace 
metals. Antioxidants act by providing electrons and easily available 
hydrogen atoms that are accepted more readily by the free radicals than are 
those of the drug being protected. Among those more frequently used in 
aqueous preparations are sodium sulfite, sodium bisulfite, hypo 
phosphorous acid and ascorbic acid. 
 In oleaginous preparations, alpha-tocopherol, butylhydroxytoluene, 
butylhydroxyanisole and ascorbyl palmitate are used. Trace metals 
originating in the drug, solvent, container or stopper can be a constant 
source of difficulty in preparing stable solutions of oxidizable drugs. The 
rate of formation of color in epinephrine solutions, for instance, is greatly 
increased by the presence of ferric, ferrous, cupric and chromic ions. Great 
care must be taken to eliminate these trace metals from the labile 
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preparations by thorough purification of the source of the contaminant or 
by using chelating agents such as calcium disodium edetate and 
ethylenediamine tetra acetic acid. 
Light can also act as a catalyst to oxidation process; sensitive preparations 
are packed in light–resistant or opaque containers. In addition since most 
drug degradations proceed more rapidly with an advanced temperature, it 
is also advisable to maintain oxidizable drugs in a cool place (Allen, 
2004).  
  
1.5.7. Factors influencing drug stability in tablet dosage forms:  
Formulation and stability difficulties are less with solid dosage forms than 
with liquid pharmaceutical preparations and this is one reason many new 
drugs first reach  the market as tablets or dry filled capsules. Factors 
influencing drug stability in tablet dosage forms include the following: 
1.5.7.1 Moisture content:  
Water soluble drugs present in a tablet dosage form will dissolve in any 
moisture which has adsorbed on the solid surface, the drug will now be in 
an aqueous environment and its decomposition could be influenced by 
many of the factors that affect the liquid dosage forms. For example 
decomposition could now occur by hydrolytic cleavage of ester or amide 
linkages in the drug molecule and hence will be affected by the pH of the 
adsorbed moisture film. Therefore moisture is considered to be one of the 
most important factors that must be controlled in order to minimize 
decomposition. It is important to minimize access of moisture during 
manufacture, storage and the correct selection of packaging system (Allen, 
2004). 
1.5.7.2 Excipients:  
Excipients can affect the stability of drug in tablet dosage form by 
increasing the moisture content of the preparation. Starch and povidone 
have particularly high water; povidone contains about 28% equilibrium 
moisture at 75 % relative humidity. However, whether this high moisture 
level has effect on stability depends on how strongly it is bound and 
whether the moisture can come into contact with the drug. Magnesium 
trisilicate causes increased hydrolysis of aspirin in tablet form because of 
its high water content (Cunningham and Scattergood, 2001). 
Other studies have identified problems with stearate salts and it has been 
suggested that these salts should be avoided as a tablet lubricants if the 
active component is subjected to hydroxide –ion-catalyzed degradation.  
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1.5.7.3. Temperature: 
 The effect of temperature change on the stability of the tablet dosage 
forms can be complicated for many possible reasons. The drug or one of 
the excipients may for example, melt or change its polymorphic form as 
temperature is increased or it may contain loosely bound water which is 
lost at higher temperatures. The relative humidity will change with 
temperature and so care should be taken to keep this at constant value.  
1.5.7.4. Light and oxygen: 
 Stability problems arise with the drugs which are susceptible to 
photodecomposition or oxidation. All the necessary precautions should be 
taken to exclude light or oxygen when storing these drugs. 
1.5.8. Protocol for stability testing: 
It is most important to ensure that a particular formulation (e.g. tablets) 
when packaged in a specific container will remain within its physical, 
chemical, microbiological, therapeutic and toxicological specifications on 
storage for a specific time period. In order to make such an assurance, a 
rigorous stability testing program should be conducted on the product in 
the form that is finally to be marketed. Since the testing period can be as 
long as two years, it has become essential to devise a technique which can 
be used during product development to speed up the identification of the 
most suitable formulation, study using accelerated storage tests to predict 
the shelf life of the drug and suitable storage conditions by using different 
chemical decomposition equations isothermal or non isothermal approach. 
Stability information from accelerated and long term testing is required to 
be provided on at least three batches manufactured to a minimum of pilot 
plant scale by the same synthetic route and using a method of a 
manufacture and procedure that simulates the final process to be used on a 
manufacturing scale. In this context pilot plan scale is taken to mean a 
minimum scale of one-tenth that of the full production process. The 
container to be used in the long term evaluation should be the same as, or 
simulate the actual packaging used for storage and distribution.  
The overall quality of the batches of drug substance subjected to stability 
testing should be representative of both the quality of the material used in 
preclinical and clinical studies and the quality of material to be made on a 
manufacturing scale. The testing should be designed to cover those 
features susceptible to change during storage and likely to influence 
quality, safety  and/or efficacy, including as necessary the physical, 
chemical and microbiological characteristics, the length of the studies and 
the storage conditions should be sufficient to cover storage, shipment and 
subsequent use.  
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1.5.8.1. Specifications for stability testing protocol: 
The specifications for the long-term testing are a temperature of 25Cº ±2 
and 60% ± 5% relative humidity (RH) for period of twelve months. For 
accelerated testing the temperature is specified as 40Cº ±2 and 75 % ± 5% 
RH for a period of six months. Other storage conditions are allowed if 
justified, in particular, temperature–sensitive drugs should be stored at a 
lower temperature which then becomes the designated long term testing 
temperature. 
 The six months accelerated testing should then be carried out at a 
temperature at least 15Cº above this designated temperature together with 
the relative humidity appropriate to that temperature. When significant 
change occurs during the six months accelerated storage testing, additional 
testing at an intermediate temperature such as 30Cº ±2/60% ± 5% RH 
should be conducted for  drug substances to be used in the manufacture of 
dosage forms tested for long-term stability at 25Cº /60 % RH . Significant 
change at 40Cº /75 % RH or 30Cº/60% RH is defined as failure to meet the 
specifications (Molzon and Sigonda, 2006). 
The long term testing is required to be continued for a sufficient period of 
time beyond 12 months to cover all appropriate re-test periods .The 
frequency of testing should be sufficient to establish the stability 
characteristics of the drug substance under the long term conditions. This 
will normally be every three months over the first year, every six months 
over the second year and then annually.  
The design of the stability programmed for the finished product is based on 
the knowledge of the behavior and properties of the drug substance and the 
experience gained from the clinical formulation studies and from stability 
studies on the drug substance (Molzon and Sigonda, 2006).  
As with the stability testing of drug substance, the testing of the product 
should cover those features susceptible to change during storage and likely 
to influence quality, safety and or efficacy. The range of testing should 
cover not only chemical and biological stability but also loss of 
preservative, physical properties and characteristic, organoleptic properties 
and where required microbial attributes. The conditions and time periods 
for long term and accelerated storage testing are the same as those outlined 
above for drug substances but with special considerations arising from the 
nature of the drug product (tablet). 
In case of tablet drug products, significant change at the accelerated 
condition is defined as a 5 percent potency loss from the initial assay value 
of a batch, any specified degradant exceeding its specification limit, 
dissolution exceeding the specification limits for 12 tablets and failure to 
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meet specifications for appearance and physical properties such as odor, 
color, delivery peractuation, friability and hardness (Molzon and Sigonda, 
2006). 
Although all pharmaceutical products have to satisfy government 
regulatory authorities, surprisingly there are no nationally or 
internationally standardized storage conditions. Storage conditions during 
stability testing vary from company to company and even within single 
company.   
Shelf life should be established for the climatic conditions of the 
destination marketplace. Recommended storage conditions should 
therefore guarantee the quality, safety and efficacy of the product for the 
designated shelf life. It is important that the expiry date and storage 
conditions are indicated on the label. Efforts regional and interregional to 
harmonize stability testing conditions offer many challenges, particularly 
for the hot and humid zone conditions. 
Climatic zones are classified into: 
    Zone I--------------Cool summer, subarctic, Ice  
    Zone II-------------Semiarid, mediterranean, marine w, coast, humid                             
                                     subtropical, tundra, highlands 
          Zone III-----------Arid 
          Zone IVa ---------Tropical dry. 
          Zone IVb----------Tropical wet 
 In October 2005, the WHO expert committee on specifications for     
pharmaceutical preparations recommended that WHO stability guidelines 
be amended to reflect conditions for zone 1V as follow: 
           Zone IVa ---30Cº/65 % RH. 
           Zone IVb ---30 Cº/75 % RH. 
The expert committee agreed that each individual member state within the 
former Zone IV would need to indicate which of these conditions (Zone 
IVa or IVb) would be applicable in its territory (Molzon and Sigonda, 
2006). 
According to WHO protocol Sudan is classified in Zone IV and the 
registration requirements of the drugs include the following stability data: 
a) Provide the results of stability testing of the formulation in each of the 
proposed marketing pack. Results should include physical as well as 
chemical tests. Data should also be provided on the product’s stability 
during any processing prior to use that may be recommended on the label 
or in product information, such as reconstitution of a powder, dilution of 
an injection, or dispersion of a tablet; b) State the proposed shelf life with 
justification in terms of the results of stability testing, and the difference 
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between release and expiry specifications; c) State storage conditions for 
the finished product; d) Stability indicating method should be used in 
testing the stability of the product; e) Complete data and information about 
degradation products should be submitted; f) With respect to both locally 
manufactured or imported products additional stability studies are required 
whenever major modifications are made to formulation, manufacturing 
process, packaging or method of preparation; g) Batches to be tested 
minimum 3 batches. h) Conditions used for accelerated and ongoing 
stability studies will be as follow (Accelerated stability studies at 40± 2Cº/ 
75± 5% RH and at least for 6 months , Real time stability studies at 30Cº 
±2/ 60% ± 5% RH and minimum for 24 months . 
             
1.6. Aspirin  
The compound, salicylic acid, from which the active ingredient acetyl 
salicylic acid (aspirin) was first derived, was found in the bark of a willow 
tree in 1763 by Reverned Edmand Stone of Chipping– Norton, England. 
The bark from the willow tree– Salix Alba– contains high levels of salicin, 
the glycoside of salicylic acid. Earlier accounts indicate that Hippocrates of 
ancient Greece used willow leaves for the same purpose to reduce fever 
and relieve the aches of a variety of illness. During the 1800s, various 
scientists extracted salicylic acid from willow bark and produced the 
compound synthetically. Then in 1853 French chemist Charles F. Gerhardt 
synthesized in primitive form of aspirin, a derivative of salicylic acid. In 
1897, Felix Hoffmann, German chemist working at the Bayer division of 
I.G.Farber, discovered a better method for synthesizing the drug. Bayer 
marketed aspirin beginning in 1899 and dominated the production of pain 
retevers until after World War I, when Sterling drug bought German– 
owned Bayer’s new. Today aspirin is registered trademark of Bayer in 
many countries around the world, but in the United Stated and the United 
Kingdom aspirin is simply the common name for acetyl salicylic acid 
(Thomson Gale, 2006). 
Chemical name of aspirin is O–Acetyl salicylic acid, 2–(acetyloxy) 
benzoic acid with the chemical formula C6H8O4. 
 
1.6.1. Physical properties of aspirin: 
Aspirin exists as colorless or white crystals or as a white crystalline 
powder, Odorless or with a faint odor of acetic acid. Melting point: 143 Cº 
Dissociation constant pka 3.5 (25Cº), it is soluble in 1 in 300 of water, 1 in 
7 of ethanol, 1 in 17 of chloroform and 1 in 20 parts of ether. 
The aqueous solubility of aspirin is increased with increase in temperature. 
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Aspirin can be formulated in several dosage forms, tablets, capsules, 
caplet, elixirs and suppositories, in various concentrations from 60 to 650 
mg. But the drug is widely used in tablet forms such as conventional, 
dispersible, effervescent, buffered, chewable, delayed release or extended 
release tablets, etc. 
1.6.2. Pharmacology of Aspirin: 
Classically aspirin is known to possess analgesic, anti-inflammatory, anti 
platelet and antipyretic properties. Biochemically, aspirin acetylates 
proteins; this is how aspirin interferes with arachidonate metabolism. Most 
pharmacological texts state that aspirin interferes with prostaglandin 
synthesis by irreversibly inhibiting cyclooxygenase, one of two major 
enzymes that act upon arachidonic acid. Cylcooxygenase exists in two 
isozymes cyclooxygenase –I or COX-I and cyclooxygenase -2 or COX-2. 
These isozymes are encoded by different genes, reside in different 
sites.COX-1 occurs in endoplasmic reticulum where as COX-2 is found in 
the nuclear envelope and not surprising has different functions. COX-1 
may be more important for hormonal regulation, hemostasis and 
thrombosis while COX-2 may be more important in the inflammatory 
response (Lee, 2006). 
Aspirin acetylates serine in both isozymes. Acetylated COX-1 can no 
longer generate prostaglandins. Acetylated COX-2 however retains the 
ability to generate metabolites of arachidonic acid that are thought to 
possess antiproliferative effects. This latter mechanism may explain why 
aspirin has been found effective in reducing the risk of colorectal cancer, 
since virtually all tissues can produce eicosanoids. The effects of aspirin 
are many and diverse. Non-salicylate NSAIDs also inhibit both isozymes 
of cycoloxygenase. However, the effects of these drugs are reversible and 
shorter-lived than the effects of aspirin. 
The effects of aspirin on platelet aggregation occur at doses much lower 
than those required for an anti-inflammatory effect.  Aspirin does not 
inhibit the action of lipooxygenase, the other major enzyme class that acts 
on arachidonic acid. (Lee, 2006) (De Noon, 2006) (Reinberg, 2006).  
 
1.6.3. Pharmacokinetics of aspirin: 
Aspirin is usually administered orally in adults, but can be given rectally as 
suppositories in children. It is rapidly absorbed from the gastrointestinal 
tract, partially hydrolyzed to salicylate on the first pass through the liver 
and is widely distributed into most tissue, poorly bound to plasma proteins. 
Following oral administration and depending on dosage form, salicylate 
can be present in serum within 5-30 minutes and peak serum 
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concentrations are attained within 0.25-2hours. Serum salicylate 
concentrations of at least 100µg/ml are required for analgesia and 
concentration of roughly 150-300µg/ml are necessary for anti-
inflammatory effects. Severe toxic side effects can occur at concentrations 
greater than 400µ g/ml. Aspirin is 99% metabolized to salicylate and other 
metabolites. The elimination half life of aspirin in plasma is about 15-20 
minutes. Salicylates and metabolites are excreted primary by the kidneys; 
almost all of the ingested dose is excreted in the urine in the form of 
metabolites, salicyluric, diglucuronides and free salicylates (Sweetman, 
2002).  
 
1.6.4. Indications of aspirin: 
Aspirin is indicated for acute myocardial infarction, arterial 
thromboembolism prophylaxis, colorectal carcinoma prophylaxis, fever, 
headache, juvenile rheumatoid arthritis, Kawasaki disease-Y, migraine, 
mild pain,  osteoarthritis, pericarditis, post myocardial infarction, transient 
ischemic attack, unstable angina prosthetic heart valves, pre eclampsia and 
vernal keratoconjunctivitis-Y(Sweetman, 2002). 
1.6.5. Side effects of aspirin: 
 Serious side effects include an allergic reaction, black bloody or tarry 
stools, nausea, vomiting and abdominal pain, uncontrolled fever, blood in 
urine or vomit, decreased hearing or ringing in the ears, seizures, dizziness, 
confusion or hallucination. Less serious effects include heart burn or 
indigestion or faint ringing in the ears.  Moreover the drug is associated 
with kidney damage, severe metabolic derangements, respiratory and CNS 
effects, strokes, fatal hemorrhages of the brain, spleen, liver, intestine, 
lungs and death. 
One of the most serious side effects of aspirin is the occurrence of Reye's 
syndrome when given to children with varicella (chickenpox) or influenza 
(flu). Although a causal relationship has not been confirmed, most 
authorities advise against the use of aspirin in children with chickenpox, 
flu, or other viral infection. If children are receiving chronic aspirin 
therapy, aspirin should be discontinued immediately if a fever develops, 
and not resumed until diagnosis confirms that the febrile illness has run its 
course and absence of Reye's syndrome (Sweetman, 2002). 
 
1.6.6. Interaction and precautions of aspirin:  
Use of aspirin with blood thinner can increase the risk of bleeding, with 
anti acid can decrease aspirin level, with B-blocker can lead to decrease 
antihypertensive effect, with ACE inhibitors can lead to decrease ACE 
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inhibitors effects, with allopurinol can lead to decrease allopurinol effect, 
with NASID can lead to increased risk of stomach ulcers, with oral 
hypoglycemic agents can lead to low blood sugar, with methotrexate can 
increase its effect and toxicity, with alcohol or nicotine can increase the 
risk of stomach ulcers and the use of aspirin can lead to foliate depletion 
(hair loss)  (www.juiceguy.com. 2006),(  www.rxlist.com , 2006)    
1.6.7. Aspirin dosage: 
Antipyretic and analgesic: Adults, 325 mg to 1 gm /day orally every three 
to four hours. Children, 10-20 mg/kg every six hours not to exceed a total 
daily dose of 3.6 gm.   
Acute rheumatic fever: Adults, 5 gm to 8 gm /day in interval 5 to 8 doses 
Chidern, 100 mg to 125 mg/kg per day in divided dose every 4-6 hours. 
Rheumatoid arthritis: Adults, 2.6- 5.4 gm PO per day in four or more 
divided doses. Children, ≤ 25 kg 60-90 mg/kg/day PO or PR in divided 
doses, > 25 kg 2.4 -3.6 gm per day in divided doses. 
Myocardial infarction prophylaxis: Adults, 75 mg-325 mg PO once a day. 
Acute myocardial infarction treatment: Adults, 160 -325 mg PO once 
daily. 
Stroke prophylaxis: Adults, 325-650 mg daily in 2-3 divided doses. 
For arterial thromboembolism prophylaxis in combination with warfarin in 
patients with prosthetic heart valves: Adults, 100 mg /day PO (Sweetman 
2002). 
1.6.8. Stability of aspirin: 
Aspirin is stable in dry air but in contact with moisture or in aqueous 
solution it undergoes hydrolysis to yield acetic acid and salicylic acid. The 
rate of decomposition is both acid and base catalyzed and is accelerated by 
heat. Maximum stability is observed at pH values between 2 and 3 because 
the amount of {OH} is decreased and thus the forward rate of reaction of 
aspirin hydrolysis is depressed (David, 2003) (Susan, 2006). 
The decomposition of aspirin has been studied in the solid state. The extent 
of the decomposition is mainly dependent on water vapor pressure and on 
temperature. Samples of aspirin stored at 35Cº, 45Cº, 60Cº, 80Cº, 100Cº 
and 110Cº in the absence of moisture showed negligible decomposition 
after 50 days. A possible mechanism for the solid state decomposition of 
aspirin was suggested to involve initial sorption of moisture by each 
particle to form water layer, diffusion of aspirin into solution and 
subsequent decomposition by acid–catalyzed hydrolysis.  
The stability of aspirin in its solid dispersion with urea or povidone was 
investigated at two accelerated storage conditions. The observed aspirin 
degradation in both systems followed the first order rate equation. The 
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water sorption ability of the two carriers as well as the alkalinity imparted 
by urea could possibly be the most important factor responsible for the 
observed acceleration of aspirin decomposition. The result also showed 
that the temperature effect was more pronounced than the humidity effect 
and generally co precipitated samples exhibited slightly higher degradation 
rates than physically mixed ones (ElBanna, 1978). 
1.6.9. Dosage forms with enhanced stability of aspirin: 
Accelerated stability testing was performed on aspirin-magaldrate double 
layer tablets as well as aspirin-maalox marketed double layer tablets 
(Ascriptin®) in order to evaluate the effect of the presence of the alkaline 
moieties of the antacid (magaldrate and maalox) on the chemical stability 
of aspirin. The results were compared simultaneously with that obtained 
from the marketed Aspro® plain tablets. The results revealed that the 
presence of the alkaline moieties in the tested tablets has increased the rate 
of aspirin decomposition and reduced its shelf-life. This effect was more 
pronounced for aspirin tablets containing magaldrate antacid. 
Determination of shelf-lives at 25°C for the prepared and the marketed 
tablets was carried out using Arrhenius plots and the results showed that 
they were 35, 34.5 and 13.5 months for Aspro®, Ascriptin® and aspirin-
magaldrate double layer tablets, respectively. The effect of storage for 50 
days and at different temperatures, on the crushing strength and the 
disintegration time of the prepared and the marketed tablets showed a 
slight decrease in the disintegration time and the crushing strength of the 
tablets as the storage temperature increased. Aspro® tablets did not 
produce the same results. The in vitro release data of the prepared aspirin-
magaldrate double layer tablets and the marketed Ascriptin® tablets stored 
for 50 days and at different storage temperatures as well as Aspro® tablets 
stored at 70°C were best fitted to the first-order kinetics model. The release 
data of Aspro® tablets stored at 50 and 60°C for 50 days were best fitted to 
Higuchi's model (Al-Gohary and Al-Kassas, 2000). 
Cunningham and Scattergood (2001) have studied a relatively simple 
acetylsalicylic acid formulation utilizing a combination of microcrystalline 
cellulose (MCC) and partially pregelatinized starch (P-PGS) as the primary 
excipients. MCC in the formulation provides the compactability needed for 
producing a tablet that withstands the mechanical stresses of the film 
coating process. Starch provides the necessary dissolution characteristics to 
the formulation and was responsible for the stability characteristic in this 
moisture sensitive enteric film coated application. The final coated tablets 
would not require the use of any specialized packing materials 
(Cunningham and Scattergood, 2001).    
 37
A study by Habib and Rogers in 1993 found that the hydrolysis of aspirin 
in an organic solvent (liposomes) at pH 4.0 was dramatically impacted (in 
some cases, minimized) with varying orientation of the acetylsalicylic acid 
molecules as well as the structural order of the liposome bilayers (Habib 
and Rogers, 1993). 
The pharmacokinetics of acetylsalicylic acid (ASA) and its main 
metabolite salicylic acid (SA) following single dose administration of a 
new chewable, buffered ASA tablet formulation and a conventional plain 
ASA tablet formulation were investigated in 12 healthy male subjects.  
The volunteers received in a randomized, crossover design two 
pharmaceutical units of both formulations containing 500 mg ASA each 
after an overnight fast on an empty stomach. ASA and SA in the collected 
plasma and urine samples were determined using an internally 
standardized validated HPLC method. Regarding the normalized extent 
parameters for ASA, an increase of about 114% for the maximum 
concentration (Cmax,norm) and about 16% for the area under the curve 
(AUC0----infinity,norm) was found for the new chewable, buffered tablet 
formulation as compared to the plain tablet. Comparing the corresponding 
parameters for the main metabolite, both formulations were statistically 
equivalent. The quotient of normalized areas (QAUC0-20min, 
norm/AUC0----infinity,norm) for ASA was higher by about 124% for the 
new formulation, indicating an increased and faster absorption during the 
first 20 min after administration. The time of the concentration maximum 
did not differ statistically. These data indicate that the new chewable, 
buffered ASA tablet formulation shows a significant benefit as compared 
to the plain ASA tablet. The new tablet produced higher plasma ASA 
concentrations in a shorter time, which is clinically important since higher 
ASA concentrations are assumed to be related to an improved analgesic 
efficacy (Lucker, 1992). 
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2. Scope of the Work 
 
Aspirin is a salicylate type of drug that possesses anti-inflammatory, 
analgesic, antipyretic and anti platelet aggregation effects. The drug is 
widely used throughout the world in different strengths. It is well-
documented that aspirin, as an ester, can be easily cleavaged and hydrolyzed 
into salicylic acid and acetic acid which necessitates that the drug being 
formulated with suitable excipients in suitable dosage form, packaged in 
suitable packaging system and stored in suitable storage conditions. 
Aspirin 75mg tablets is preferred in case of antithrombotic actions since the 
drug upon long time usage is known to have a potential anti platelet 
aggregation effect in this strength. 
Concerning Sudan, climatic conditions favor breakdown of aspirin during 
manufacturing and storage owing to the temperature and humidity 
characterizing the country. This might necessitate careful excipients and 
operating procedures selections. 
The scope of the present study is to apply full factorial design in order to 
examine, in a comparative manner, the impact of excipients, dosage form 
formulations, packaging systems and storage conditions on physicochemical 
performance of aspirin.  
Moreover, the study is designed in a way to explore, specifically, the 
contribution of formulation variables on dosage form design of this drug 
using aspirin 75mg as chewable, effervescent and conventional tablet 
models. 
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3. Materials and Methods 
 
3.1. Materials: 
 
 The following materials have been used during the experimental part of the        
research:  
Aspirin reference standard and raw material were products of China 
associated.co.LTD, China. 
 Mannitol was a product of Roquette sreres, France.  
 Starch was a product of Rhodia trading, Italy. 
Sorbitol, Povidone (PVP), Saccharin sodium, Talc, Citric Acid and Sodium 
bicarbonate were products of Andenex- Chemie-GmbH, Germany. 
All these products have been kindly supplied by City pharma laboratories. 
 Dry orange flavor was donated by  Marwa pharma laboratories.  
Sodium hydroxide, hydrochloric acid, phenol red, sodium 1-heptane 
sulfonate, acetonitrile, glacial acetic acid, formic acid and salicylic acid USP 
were analytical grade from different commercial sources. 
 
3.2. Instruments and Apparatus: 
The following instruments and equipment or apparatus were used during the 
course of the work: 
Tablet compression machine (rotary press 10 sets of punches and dies – 
KMP 10-kambert Machinery Co. Ahmed Abad -India). 
Single punch machine (Erweka –GmbH-D-63150– Heusenstamm-Typ: EK-
O- serial No: K0000151, Germany). 
Friability tester (Erweka – GmbH-D-63150– Heusenstamm–Typ: TA100 – 
serial No: 112650.125F, Germany). 
 Hardness tester (GmbH-D-63150– Heusenstamm- Typ: TBH 210 – serial 
No: 112661.125F, Germany). 
Granulator (GmbH-D-63150– Heusenstamm -Typ:TG 2000 – serial No: 
72547.10cf, Germany). 
High speed mixer (GmbH-D-63150– Heusenstamm -Typ: SW1/S – serial 
No: 72457-0837, Germany). 
Disintegration tester (Erweka – GmbH-D-63150– Heusenstamm–Typ: 
ZT302 – serial No: 112524.10cf, Pn =2000 w, In: 15A, U: 230 v, F: 50 Hz. 
Germany). 
 Cubic mixer (Kevlab -type VMD- Serial No. 300000000259- Kevin 
engineering Pvt. Ltd-Ahmed Abad- India).  
 Analytical balances (Sartorius AG Gottingen- CE 0111 M-LA 230 P, 
Germany). 
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 HPLC: Chromatographic system U.V detector-280nm, 4.0 mm x 30 cm 
column containing L1(ODS),Flow rate 2ml/min, pump Syknm Isocratic 
pump, S3210 UV/VIS Detector –S1122 Solvent delivery system, Germany). 
Stability chamber (humidity cabinet- Remi instruments LTD- Mumbai- 
400053-Catalogue NO: CH-105.11/03-Serial No: IHC-213, India).  
Cylinders, pipettes, burettes, flasks and beakers (Schott Duran-Germany).  
 
3.3. Methods: 
 
3.3.1. Experimental design and dosage form formulations: 
The screening design selected for the development of the chewable tablets 
was 2³ full factorial experiments design, in which three variables, namely, 
mannitol or sorbitol (X1), Mannitol or Sorbitol loading level(X2) starch or 
PVP (X3), each investigated at two levels (-1 and +1) within the possible 8 
iterations (formulation runs) for their main and interactive effects on 
physical and chemical characters of the developed formulations. (See table I) 
For effervescent tablets 3² full factorial experiments design was used, in 
which two variables, namely, percentage of the amount of citric acid and 
sodium bicarbonate mixture in the formula (X1) and the ratio of citric acid to 
sodium bicarbonate in this mixture (X2), each investigated at three levels 
within possible 9 iterations (formulation runs) for their main and interactive 
effects on physical and chemical characters of the developed formulations. 
(See table VII).  
 
3.3.2. Preparation of chewable tablets: 
 
According to different formulations summarized in Table II, the required 
amount of aspirin was weighed, compressed into slugs and crushed to obtain 
small granules, which were sized through mesh-20. The amount of 
excipients (mannitol or sorbitol, dry orange flavor, saccharine sodium, talc 
and starch or PVP) were weighed and mixed with aspirin granules in cubic 
mixer (100 rpm) for 20 minutes. Then the final mixture was compressed into 
tablets using rotary press tablet machine with flat and break line 7 mm punch 
and die set after adjustment of suitable compression force and required 
weight. The obtained tablets weighing 120 mg and containing 75 mg of 
aspirin were finally packed in strip and blister package systems and placed 
in stability chamber adjusted at 50C°±2 and 75%±5 relative humidity. 
Tablets of different formulas conceived were tested for their content 
uniformity, free salicylic acid content, weight variation, friability and 
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hardness initially and after one month, two months and three months. 
Results were summarized in tables III, IV, V and VI.  
 
3.3.2.1. Upgrade of chewable tablet formula: 
 
From the results of three months stability studies of the eight formulations of 
chewable tablets, new formulations containing mixtures of both sorbitol and 
mannitol in different ratios were prepared. The dry orange flavor was 
omitted owing to its color change effect upon exposure of tablets to light. 
New three formulations were prepared in ratios of sorbitol to mannitol, 1:2, 
1:1 and 2:1. The three formulations are summarized in table XI. 
These formulations were prepared and packed as described before under 
3.3.2. 
Tablets within the three formulations were tested for their content 
uniformity, free salicylic acid content, weight variation, friability and 
hardness at zero, one month, two month and three months time. The results 
are summarized in tables XII, XIII, XIV and XV. 
In order to upgrade the best found formula for the large-scale production, 
some powder studies were done. The particle size analysis and powder flow 
of individual, mixture and granulated powders of aspirin, mannitol and 
sorbitol were carried and optimization of mixing process of these three 
formulations powders was done. Also to select the best manufacturing 
process, the most-promising formula was firstly prepared by direct 
compression, the amounts of  aspirin, mannitol and sorbitol were weighed, 
mixed in cubic mixer for 20 minutes and the amounts of talc and starch 
needed for yield was added, mixed in cubic mixer for 20 minutes. Then the 
mixture of powder was directly compressed in rotary press tablet machine. 
The tablets obtained were tested for their content uniformity, free salicylic 
acid content, weight variation, friability, hardness, thickness and 
disintegration. The results are summarized in table XVIII. Secondly the 
formula was prepared by dry granulation method, the amounts of aspirin, 
mannitol and sorbitol were weighed and mixed in cubic mixer for 20 
minutes. The mixture obtained was compressed into slugs then the slugs 
were granulated by granulator and sized through mesh number 30, the 
amount of talc and starch needed for yield were added and mixed in cubic 
mixer for 20 minutes. Then the mixture was compressed in rotary press 
tablet machine. The tablets obtained were tested for their content uniformity, 
free salicylic acid content, weight variation, friability, hardness, thickness 
and disintegration. The results are summarized in table XVIII.  
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Comparing the results in (table XVIII), the best method of production was 
selected. 
 Two trials (formula CTI and CT2) of formula CHF4B were manufactured 
by dry granulation method in large scale operation using the real tablet 
machine line in pharmaceutical industry. The obtained tablets weighing 120 
mg and containing 75 mg of the drug were finally packed in blister pack 
system and placed in stability chamber adjusted at 40C°±2 and 75%±5 
relative humidity. 
Finally these tablets were tested for their appearance, content uniformity, 
free salicylic acid content, weight variation, friability and hardness in six 
months accelerated stability studies. The results are summarized in tables 
XIX and XX. 
 
3.3.3. Preparation of effervescent tablets: 
 
According to different formulations are summarized in Table VIII, the 
quantity of aspirin, citric acid, sodium bicarbonate, starch, saccharin sodium 
and 50% of the quantity of talc were weighed and mixed in high speed mixer 
for 10 minutes. Then the obtained mixture was compressed into slugs using 
Erweka- single punch tablet machine and crushed by Erweka-granulator to 
obtain small granules sized through mesh-20, lubricated and mixed with the 
rest of 50 % talc in high speed mixer for 10 minutes and compressed into 
tablets using rotary press tablet machine with flat and break line 7 mm punch 
and die set after adjustment of suitable compression force and required 
weight. The obtained tablets weighing 100 mg, 120mg or 145 mg and 
containing 75 mg of aspirin were finally packed in blister package system 
and placed in stability chamber adjusted at 50C°±2 and 75%±5 relative 
humidity. 
Tablets of different formulations conceived were tested for their content 
uniformity, free salicylic acid content, weight variation, friability, hardness 
and disintegration time. The results are summarized in table IX. 
 
3.3.4. Preparation of conventional tablets: 
 
The quantity of aspirin, starch, saccharin sodium and 50% of the quantity of 
talc were weighed and mixed in high speed mixer for 10 minutes. Then the 
obtained mixture was compressed into slugs using Erweka single punch 
tablet machine and crushed by Erweka granulator to obtain small granules 
sized through mesh-20, lubricated and mixed with the rest of 50 % talc in 
high speed mixer for 10 minutes and compressed into tablets using rotary 
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press tablet machine with flat and break line 7 mm punch and die set after 
adjustment of suitable compression force and required weight. The obtained 
tablets weighing 100 mg and containing 75 mg of the drug were finally 
packed in blister package system and placed in stability chamber adjusted at 
50C°±2 and 75% ±5 relative humidity. 
Tablets were tested for their content uniformity, free salicylic acid content, 
weight variation, friability and hardness and disintegration time. The results 
are shown in table X.  
 
3.3.5. Compressibility Index tests for chewable tablets: 
100 mg of the powder mixture of aspirin and excipients was weighed, 
transferred to a measuring cylinder of bulk density measurement apparatus. 
Bulk density was measured immediately, then the cylinder was tapped for 
500 times and the final or tapped density was measured. The results of CI 
are shown in table I. 
    
3.3.6. Weight variation tests: 
Twenty tablets of each formulation were weighed individually using 
analytical balance and standard deviations of these weights were calculated 
(BP2000). 
 
3.3.7. Hardness tests:  
Twenty tablets of each formulation were subjected individually to crushing 
force using Erweka Hardness tester. The mean of these readings were 
calculated (BP2000). 
 
3.3.8. Friability tests: 
Twenty tablets of each formulation were weighed and tumbled in Erweka 
friabilator for 4 minutes with 25 rpm. The tablets were dedusted and 
weighed. The friability was calculated as the percentage of weight loss of the 
tablets. (According to BP, the accepted limit of weight loss is 0−1 %) 
(BP2000).  
 
3.3.9. Content of aspirin in chewable tablets: 
Twenty tablets were weighed and powdered. To a quantity of the powder 
containing 0.5 gm of aspirin, 30 ml of 0.5 M sodium hydroxide VS was 
added, boiled gently for 10 minutes and the excess of alkali was titrated with 
0.5 M HCL VS using phenol red as indicator. The operation was repeated 
without the substance being examined. The difference between titrations 
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represents the amount of sodium hydroxide required. Each 1 ml of 0.5 M 
sodium hydroxide VS is equivalents to 45.04 mg of C6H8O4    
The content percent was calculated according to the following equation: 
The content % = the difference in readings x 45.04 x correct factors of Na 
OH and HCL x 100 / 500 (BP2000). 
 
3.3.10. Free salicylic acid test in chewable tablets: 
The quantity of the powdered tablets containing 0.2 gm of aspirin was shake 
with 4 ml of ethanol (96 %), diluted to 100 ml with water at a temperature 
not exceeding 10 Cº and filtered immediately. 50 ml of the filtrate was 
transferred to a Nessler cylinder, 1 ml of freshly prepared ammonium iron 
III sulphate solution RI was added, mixed and allowed to stand for 1 minute. 
Any violet color produced should not be more intense than that obtained by 
adding 1 ml of freshly prepared ammonium iron III sulphate solution RI to a 
mixture of 3 ml of freshly prepared 0.01% w/v solution of salicylic acid, 2 
ml of ethanol 96% and sufficient water to produce 50 ml contained in a 
second Nessler cylinder (0.3%) (BP2000). 
 
3.3.11. Content of aspirin in effervescent tablets 
Twenty tablets were weighed and powdered. Quantity of the powder 
equivalent to 100 mg aspirin was transferred to container containing 20ml 
diluting solution of 1:1 solution of acetonitrite and formic acid and shaken 
for 10 minutes to make stock solution which is then diluted with the diluting 
solution in 1:9 ratios to make the assay preparation. The rest of stock 
solution was reserved for the test of free salicylic acid limit. 
An accurately weighed quantity of reference standard aspirin was dissolved 
in the diluting solution to obtain standard solution of known concentration 
equivalent to 0.5mg/ ml.   
The chromatographic system (the liquid chromatograph) was equipped with 
a 280 nm detector and a 4.0 mm x 30 cm column containing packing LI. 
Mobile phase was composed of 2 gm of sodium 1-heptane sulfonate 
dissolved in a mixture of 850 ml of water and 150 ml of acetonitrile and 
adjusted with glacial acetic acid to a pH 3.4. The flow rate was set at 2ml per 
minute. The standard preparation was chromatograghed and the peak 
responses were recorded as directed in the procedure.   
 Equal volumes (10 µL) of the standard preparation and the assay 
preparation were separately injected into the chromatograph. The 
chromatograms were recorded and the responses were measured for the 
major peaks. The quantity in mg of aspirin in the portion of tablets was 
calculated by the formula: 
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                                                    200 C (ru/rs) 
In which C is the concentration in mg per ml of Aspirin RS in the standard 
preparation and ru and rs are the peak responses of Aspirin obtained from the 
assay preparation and the standard preparation respectively (USP2004).  
 
3.3.12. Free salicylic acid test in effervescent tablets: 
Mobile phase and diluting solution were prepared as described previously in 
the assay.  
An accurately weighed quantity of salicylic acid RS was dissolved in the 
standard preparation prepared as directed in the assay, to obtain a standard 
solution having a known concentration of about 0.015 mg of salicylic acid 
per ml. 
The stock solution prepared as described for assay preparation in the assay 
was used as test solution.  
Chromatographic conditions were the same as that described in the assay 
upon injection of standard and test solution. The percentage of salicylic acid 
in the portion of tablets was calculated and taken by the formula: 
                2000(C/QA) (ru/rs) 
In which C is the concentration in mg per ml of salicylic acid RS in the 
standard solution .QA is the quantity in mg of aspirin in the portion of tablet 
taken as determined in the assay, and ru and rs are the peak responses of 
salicylic acid obtained from the test solution and the standard solution 
respectively, not more than 3% was found (USP2004). 
  
3.3.13. Disintegration test of aspirin effervescent tablet formulations: 
A tablet of each formulation was placed in a beaker containing water at 25 
C° and the evolution of numerous bubbles of gas around the tablet or its 
fragments was observed till the gas ceased. The operation was repeated on 
five other tablets. According to BP2000, the tablets comply with the test if 
each of the six tablets used disintegrates within 5 minutes (BP2000).     
 
3.3.14. Disintegration test of aspirin conventional tablets: 
Six tablets were subjected to this test. One tablet was introduced into each 
tube of Erweka- disintegration tester with addition of a disc. The assembly 
was suspended in the beaker containing water and the apparatus was 
operated for 15 minutes. The assembly was removed from the liquid and 
detected for any fragment of tablet remains. The result is summarized in 
table (X) (BP2000). 
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3.3.15. Statistical data analysis: 
The derived different parameters concerning drug and dosage form 
assessment in all tested and scaled-up batches were analyzed for variation 
significance using ANOVA (two-sided test) at 95% confidence interval (CI 
95%). The operation was aided by the software Microcal (TM) origin® (V8, 
2005, Microcal software Inc.MA, USA). A result of p< 0.05 was considered 
significant. Summary of the analysis is contained in tables I and VII.   
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                                      4. Results and Discussion 
 
It should be emphasized that formulation simplicity, additives 
inexpensiveness, versatility, compatibility and ease of processing were the 
main cornerstones for all tablet formulations that were developed and 
examined in this study.  
4.1. Chewable Tablets 
Table I shows the complete layout of the experimental design adopted for 
the development of acetylsalicylic acid chewable tablets to investigate the 
possible influences that some formulation variables might have on the 
tablets’ performance. Respective formulations of the design appear in Table 
II. 
Table I 
Lay out of the 23 full factorial designs, with its coded and actual values, for 
development of acetylsalicylic acid chewable tablets 
Formula code Filler type
(X1) 
filler loading %
(X2) 
Binder type 
(X3) 
CI* (%) 
CHF1 +1 -1 +1 13.07 
CHF2 -1 +1 +1 5.12 
CHF3 -1 +1 -1 17.17 
CHF4 +1 +1 -1 23.17 
CHF5 +1 +1 +1 13.74 
CHF6 -1 -1 -1 3.13 
CHF7 -1 -1 +1 14.66 
CHF8 +1 -1 -1 11.12 
 Actual values  
Coded values X1 X2 X3  
-1 Mannitol 10% w/w 5% w/w starch  
+1 Sorbitol 25% w/w 5% w/w pvp  
 
Table II 
Formulations of acetylsalicylic acid chewable tablets in the 23 factorial design.  
Amount of ingredients are equivalent to 100 tablets for each formulation 
Ingredients (g) Formulations 
 CHF1 CHF2 CHF3 CHF4 CHF5 CHF6 CHF7 CHF8 
Acetylsalycilic 
acid 
7.50 7.50 7.50 7.50 7.50 7.50 7.50 7.50 
Mannitol - 3.16 3.16 - - 1.00 1.00 - 
Sorbitol 1.00 - - 3.16 3.16 - - 1.00 
PVP 0.50 0.63 - - 0.63 - 0.50 - 
Starch - - 0.63 0.63 - 0.50 - 0.50 
Talc 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 
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4.1.1. The influence of filler type and loading level on powder 
flow characteristic of acetylsalicylic acid chewable tablet 
formulations prior to compression: 
Figure 1 is a 3D surface plot concerned with powder flow characteristics of 
tablet formulations in the 23 design at fixed binder type (X3). The plot shows 
that formulations containing only sorbitol as filler are associated with 
comparative high compressibility indices (CI) up to 23% whereas those 
composed of mannitol revealed relative low values of CI. As evident from 
the plot, loading level of the filler (varies from 10 to 25% w/w) has an effect 
on the flow characteristics of the formulations’ powders and the high loading 
levels amplified such effect.  
 
 
 
Fig. 1 
Surface plot for the influence of variables X1 (filler type) and X2 (filler loading level) on 
powder flow characteristics (measured by CI) of aspirin chewable tablet formulations in 
the factorial design, 
(CI =12.6475+2.6275*X1 + 2.1525*X2 + 1.0275*X1X2 – 0.87*X12 - 4.37*X22 + e) 
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Similar results could be obtained from analysis of regression coefficient 
accompanying variables X1 and X2, which appear in the polynomial 
regression equation attached in figure 1. Coefficients associated with both 
variables X1 (filler type) and X2 (filler loading level) are numerically similar 
(2.6275 and 2.1525, respectively) and have the same positive mathematical 
sign. Moreover, interaction between the two variables was shown to affect 
the values of CI (coefficient associated with the term X1X2 in the equation is 
approximately half that of the main variables, 1.0275).  
A simple indication of the ease with which a material can be induced to flow 
is given by application of compressibility index (CI) which has been 
described under (3.3.5). Values of CI below 15% usually give rise to good 
flow characteristics, but readings above 25% indicate poor flowability and 
between these two values, less than optimum performance might be 
anticipated (Marshall, 1986).  
The results imply that compared to sorbitol, presence of mannitol in 
considerable amount enhances flow of the formulation powders and such 
influence is prominent when pvp is incorporated as binder. It is well 
documented that mannitol is commonly used as an excipient in the 
manufacture of chewable tablet formulations because of its negative heat of 
solution, sweetness, and ‘mouth feel’ (Herman, et al., 1988).  
Moreover, mannitol formulations typically have poor flow characteristics 
and usually require fairly high lubricant levels. However, it is not the case 
here as formulations containing high loading levels of mannitol revealed the 
best flow characteristics among others based on values of CI associated with 
different formulations.  
In fact this might be attributed to the granular form of mannitol utilized in 
this study (Molokhia, et al., 1987). It should be emphasized that although 
expensive, mannitol is of particular value since it is not hygroscopic and 
may thus be used with moisture-sensitive drugs like aspirin, the model drug 
of the present study (Allen 2000; Yoshinari, et al., 2003). 
As shown in figure 1 and table I a chance does exist for controlling CI of 
formulations via combination of mannitol and sorbitol in different ratios and 
such combination serves dual functions, lower the cost of the formulations in 
one hand and enhance product stability on the other hand.  
4.1.2. The influence of binder type and filler loading level on 
powder flow characteristic of aspirin chewable tablet 
formulations prior to compression : 
Figures 2a and 2b are line plots concerned with powder flow characteristics 
of tablet formulations which appeared in the 23 design. The plots show that 
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formulations containing starch (5%) as binder are associated with 
comparative high compressibility indices (CI) up to 23% with high loading 
level of filler whereas those composed of PVP revealed relative low values 
of CI. But with low loading level of filler starch revealed the lowest values 
of CI. It has been reported that compressibility index is a line function of 
moisture content (Hollenbeck, 2002).  
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Fig.2 
The effect of filler type and filler loading level on CI of aspirin chewable tablet 
formulations when: (a) Starch is used as binder. (b) PVP is used as binder 
 
4.1.3. The influence of filler type, filler loading level and binder type on 
hardness of produced acetylsalicylic acid chewable tablet formulations: 
 
Figure 3a and 3b are line plots concerned with hardness characteristic of 
aspirin chewable tablets. The plots show that formulations containing 
sorbitol as filler are associated with a comparative high hardness value 
irrespective of the binder used, whereas those composed of mannitol 
revealed low value of hardness. Moreover, loading level of the filler was 
shown to be a determining factor for tablet hardness as formulations 
containing high loading level of filler (up to 25%) revealed a comparative 
high hardness values. Although non significant (p≥ 0.05) formulations 
composed of PVP as binder revealed high values of hardness compared to 
those containing starch.  In fact, starch as dry powder exhibits a weak 
binding effect (Rumbic and Kottke, 1996)and its influence on hardness 
seems to be more profound with high loading level of filler than low level. 
 
 51
filler type
sorbitolmannitol
M
ea
n 
ha
rd
ne
ss
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
filler loading level
25 % loading level
10% loading level
filler type
sorbitolmannitol
M
ea
n 
ha
rd
ne
ss
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
filler loading level
25 % loading level
10% loading level
 
                             (a)                                                         (b) 
Fig.3 
The effect of filler type and filler loading level on hardness of aspirin chewable tablet 
formulations when: (a) Starch is used as binder. (b) PVP is used as binder 
 
It is evident from the two figures (3a and 3b) that formulations containing 
PVP as binder are associated with equal values of hardness when using 
sorbitol or mannitol as filler. However, with formulation containing starch as 
binder, only those composed of sorbitol as filler have revealed a comparative 
high hardness level.  
PVP and starch are hygroscopic excipients.  When used with sorbitol, very 
hydroscopic filler, water uptake increases to a level which can enhance their 
compressional deformation and consolidation properties upon application of 
minor compression load, thereby increasing the tablet strength (hardness) 
( Kontny and Conners, 2006). 
 
4.1.4.  The influence of filler type and loading level, and binder type on 
friability character of aspirin chewable tablet formulations: 
 
Figures 4 shows how tablet friability varies with respect to the setting of 
type and loading level of filler and the incorporated binder. 
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Fig.4: Fitted Surface plot showing the relation between friability of aspirin chewable 
tablet formulations, type and loading level of utilized fillers 
at 5% level of PVP as a binder. 
 
It is evident from figure4 that with 5% level of PVP as a binder, the loading 
level of the included filler rather than the filler type has a profound influence 
(t’ test, p<0.05) in determining tablet friability. Most of tablets prepared with 
only 10% of filler showed less weight loss (satisfactory friability) compared 
to those containing 25% w/w filler. This might be due to the effectiveness of 
PVP, at the specified loading level, to offset the attrition behavior of 
mannitol and/or sorbitol at the 10% loading level of each. However, 5% 
loading level of PVP could possibly be insufficient to compensate for the 
attrition behavior of the two fillers when present in large amount (Becker, et 
al., 1997). 
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Fig. 5: Fitted Surface plot showing the relation between friability of aspirin chewable 
tablet formulations, type and loading level of utilized fillers 
at 5% level of starch as a binder. 
 
The same could be applied when starch is considered as binder (Fig5) 
although tablets with PVP as binder were capable to reserve a low friability 
more than those with starch when both were tested under the same test 
condition. In other words, the finding explores the exaggerated strength of 
the bonding index of PVP compared to that of starch (Stubberud, et al., 
1996) and its suitability. However, for chewable tablet formulation this 
might be limited by hygroscopicity (Kibbe, 2007)  
 
4.1.5.  The influence of filler type and loading level and binder type on 
the weight variation character of aspirin chewable tablet 
formulations: 
Contour plot sections presented in figures 6 shows how the weight variation 
characteristic of aspirin chewable tablets varies with respect to the setting of 
type and loading level of filler and the incorporated binder.  
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Fig.6: Fitted Surface plot showing the relation between weight variation of aspirin 
chewable tablet formulatipons, type and loading level 
of utilized fillers at 5% level of PVP as a binder. 
The two plots show that in presence of PVP as a binder, the loading level of 
the filler has a profound influence on weight variation feature irrespective of 
the filler used where reducing the amount of filler from 25 to 10% w/w has 
resulted in rising of weight variation from 2 to 5% (calculated as %SD) 
among manufactured chewable tablets (Fig6). However, this might not be 
the case when utilizing starch as a binder since increasing of weight 
variation among produced chewable tablets was recognized with formulation 
containing high loading level of filler (Fig7). With both PVP and starch, 
inclusion of either sorbitol or mannitol seems to have no or little effect on 
weight variation character as the two figures show. Moreover, all examined 
tablets were within the limit of the allowed 5% average deviation (BP, 
2000). Since variation in weight among tablets is strongly related to the 
inconsistent flow of powder formulation from hopper to compression zone 
in the compression machine, the findings could be attributed to the non-
uniform flow imparted to the powder formulation when these fillers are 
present in large amounts. In general, it is the flow characteristics of the filler 
incorporated which determine the overall flow behavior of the formula.  
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Fig.7: Fitted Surface plot showing the relation between weight variation 
of aspirin chewable tablet formulations, type and 
loading level of utilized fillers at 5% level of starch as a binder. 
 
4.1.6. The influence of filler type, filler loading level and binder type on 
the content of aspirin and free salicylic acid tests of chewable tablet 
formulations: 
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                              (a)                                                         (b) 
Fig.8 
The effect of filler type and filler loading level on content percent of aspirin chewable 
tablet formulations when: (a) Starch is used as binder. (b) PVP is used as binder 
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Figure 8a and 8b are line plots concerned with aspirin content (assay) in 
chewable tablets. The plots show that formulations containing starch as 
binder and high or low loading level of sorbitol as filler are associated with 
comparative more acceptable values of assay (around 102%) whereas those 
composed of high or low loading level of mannitol with starch as binder 
revealed more non acceptable values of content range (high content up to 
111%) out of range. 
On the other hands, formulations containing PVP as binder and high loading 
level of mannitol results in comparatively more acceptable values than those 
composed of low loading level. On the contrary, with PVP, as binder, more 
acceptable values of content are shown with low loading of sorbitol as filler 
(103%).  
Table III shows that all the chewable tablet formulations have passed the 
free salicylic acid tests which, in turn, might indicate insignificant impact of 
filler type, filler loading level or binder type in the results of free salicylic 
acid tests of the tablets.   
Table III 
The results of quality control tests of aspirin chewable tablet formulations at zero time 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEST CHF1 CHF2 CHF3 CHF4 CHF5 CHF6 CHF7 CHF8 
Hardness(N) 2.16 4.05 2.825 4.596 4.89 1.74 2.38 1.82 
Friability (%) 0.41 1.99 0.76 0.38 0.29 0.63 0.40 0.46 
Weight 
variation (SD±) 
 
   5 
 
3.43 
 
4.23 
 
4.04 
 
3.36 
 
2.9 
 
4.59 
 
 3.6 
Content% 103.3 102 107.6 104.3 115.1 111.6 111.6 105 
Free.S.A  Comply  Comply Comply Comply Comply Comply Comply Comply 
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4.1.7. The influence of excipients and packaging system on the 
physicochemical characteristics of aspirin chewable tablet formulations 
tested under stress conditions: 
 
4.1.7.1. Hardness: 
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                              (a)                                                      (b) 
 
Figure.9 
Relationship between the results of hardness tests of aspirin chewable tablet 
formulations, after three months accelerated stability study when using: 
(a) Blister pack. (b) Strip pack 
 
Table IV 
The results of quality control tests of aspirin chewable tablet formulations in one 
month accelerated stability study 
Conditions: 50 C° ± 2, 75% ±5 RH 
TEST PACK CHF1 CHF2 CHF3 CHF4 CHF5 CHF6 CHF7 CHF8 
Strip 2.5 6.1 2.48 4.5 7.2 1.74 5.5 1.84 Hardness 
(N) Blister 4.9 6.5 2.6 4.55 8.16 1.76 6.42 1.99 
Strip 0.3 0.49 0.59 2.5 0.22 0.6 0.3 0.34 Friability 
(%) Blister 0.11 0.8 0.43 0.23 0.O96 0.57 0.2 0.36 
Strip 4.1 3.2 7.96 3.86 3.8 4.1 5 3.9 Weight 
variation(SD±) Blister 4.5 2.9 6.03 5.14 3.2 4 5.6 3.13 
Strip 100.1 101.9 99.8 103.6 107.5 111.7 100.9 98 Content% 
Blister 99.4 102.7 99 104.3 109 95.9 90.6 93.9 
Strip Not 
comply 
Not 
comply
Not 
comply
Comply Not 
comply 
Comply Not 
comply
Comply 
Free S.A 
Blister Not 
comply 
Not 
comply
Not 
comply
Comply Not 
comply 
Comply Not 
comply
Comply
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Table V 
The results of quality control tests of aspirin chewable tablet formulations in two 
months accelerated stability study 
Conditions: 50 C° ± 2, 75% ±5 RH 
TEST PACK CHF1 CHF2 CHF3 CHF4 CHF5 CHF6 CHF7 CHF8 
Strip 2.8 4.8 2.56 4.6 7.11 2 4 2.18 Hardness 
(N) Blister 5.3 7.35 2.7 4.78 7.81 2.8 3 1.92 
Strip 0.34 0.28 0.48 0.23 O.31 0.4 0.35 4.1 Friability 
(%) Blister 2.75 0.14 5.3 0.41 0.22 0.5 0.4 0.24 
Strip 4 3.8 4.87 3.78 3.4 3.9 4.1 3.8 Weight 
variation 
(SD) 
Blister 4.7 2.65 4.07 3.28 4.3 4.6 5.4 3.8 
Strip 99.4 97.5 100.5 99.7 101.2 103 96 96.4 Content% 
Blister 88.6 95.9 99.6 96.7 98.96 94 95 100.7 
Strip Not 
comply 
Not 
comply 
Not 
comply 
Comply Not 
comply 
Comply Not 
comply 
Comply Free S.A. 
Blister Not 
comply 
Not 
comply 
Not 
comply 
Comply Not 
comply 
Comply Not 
comply 
Comply 
 
Figure 9a is a line plot of hardness characteristic (shown in tables III to VI) 
of aspirin chewable tablet formulations, packed in blister pack and stored at 
accelerated conditions. The plot shows that formulations of acetylsalicylic 
acid chewable tablets containing PVP as binder and packed in blister packs 
are characterized with a marked increase in hardness after one month storage 
at accelerated conditions and then the hardness dropped to lower values. The 
same could be traced from comparative visualization of table IV and V 
(CHF1, CHF2, CHF5 and CHF7). Almost all formulations after three 
months storage show the lowest hardness values (Table VI). Increase in 
water uptake by more hygroscopic excipient (PVP) leads to decrease tablet 
strength (Uhumwangho and Okor, 2005). 
 On other hands formulations containing starch as binder, packed in blister 
pack and stored at accelerated conditions are associated with no change in 
hardness values with time (Table IV,V and VI)( Formula CHF3, CHF4, 
CHF6 and CHF8). 
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Table VI 
The results of quality control tests of aspirin chewable tablet formulations in three 
months accelerated stability study 
Conditions: 50 C° ± 2, 75% ±5 RH 
TEST PACK CHF1 CHF2 CHF3 CHF4 CHF5 CHF6 CHF7 CHF8 
Strip 2.9 4.88 2.3 4.37 7.66 1.5 3.5 2.3 Hardness 
(N) Blister 3.94 6.021 2.49 4.7 6.0 2.03 2.3 2.1 
Strip 0.4% 0.32% 0.54% 0.31% 0.29% 26.7% 0.41% 0.5% Friability 
Blister 3.35% 16.178% 0.4% 0.23% 0.14% 3.07% 0.21% 0.28% 
Strip 4.9 4.1 5.11 4.8 3.8 5 4.5 4.1 Weight 
variation Blister 5.14 3.7 5.04 4.8 4.5 3.1 7 4.4 
Strip 98.1% 93.8% 108.1% 105.8% 102.4% 97% 98.2% 100.3%Content% 
Blister 94.8% 99.8% 99.1 101.5% 97.3% 90% 93% 99% 
Strip Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Free S.A 
Blister  Not 
comply 
Not 
Comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
 
Figure 9b is a line plot of the hardness characteristic (shown in tables III to 
VI) of aspirin chewable tablets packed in strip pack and stored at accelerated 
conditions (50 C° ± 2, 75% ±5 RH). The finding explores that water proof 
protection obtained by strip pack is, to some extent, similar to that obtained 
by blister pack made from PVC, which is not enough to protect aspirin 
chewable tablets from atmospheric moisture especially when formulated 
with hygroscopic excipients. 
 
4.1.7.2. Friability: 
 
It is evident from figure 10a that friability feature among all chewable tablet 
formulations tested in the final strip pack at accelerated conditions for 3 
months did not reveal significant variation with respect to this feature ( 
Tables III to VI). However, exception does exist for formulation CHF6 
which exhibited higher friability by the end of 3 months.  
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                           (a)                                                     (b) 
 
Figure.10 
Relationship between the results of friability tests of aspirin chewable tablet 
formulations after three months accelerated stability study 
when using: (a) Strip pack. (b) Blister pack 
 
Figure 10b is a line plot of the friability characteristic (shown in tables III to 
VI) of aspirin chewable tablets packed in blister pack and stored at 
accelerated conditions (50 C° ± 2, 75% ±5 RH). The plot shows that 
formulations containing mannitol as filler, packed in blister pack and stored 
at accelerated conditions were associated with in comparative increase in 
weight loss with time whereas those composed of sorbitol showed no 
significant change in weight loss with time. Mannitol, in these formulations, 
was used as powdered mannitol which was reported to impart high 
friabilities to the final dosage forms especially upon exposure to unfavorable 
humidity and temperature conditions (Joshi and Duriez, 2004).   
 
4.1.7.3. Weight variation: 
Figure 11a is a line plot of the weight variation characteristic (shown in 
tables III to VI) of aspirin chewable tablets packed in strip pack and stored at 
accelerated conditions. The plot shows that almost all formulations revealed 
slight change in standard deviation of the tablets weights with time. 
Formulae 3 and 6 show significant increase in standard deviation of the 
weight with time.        
Figure 11b is a line plot of the weight variation feature (shown in tables III 
to VI) of aspirin chewable tablets packed in blister pack and stored at 
accelerated conditions. The plot shows that all formulations revealed 
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significant increase in standard deviation of tablets weights with time. This 
finding might be attributed to absorption of atmospheric moisture and 
adsorption of some hydrophobic ingredients (aspirin, talc) into PVC blister 
pack with time (Guillory and Poust, 1996)     
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                              (a)                                                      (b) 
Figure.11 
Relationship between the results of weight variation tests of aspirin chewable tablet 
formulations after three months accelerated stability study 
when using: (a) Strip pack. (b) Blister pack 
 
 
4.1.7.4. Content of aspirin and free salicylic acid tests:   
 
It is evident from figures 12a and 12b that acetylsalicylic acid content (%) 
among all chewable tablets formulations tested in final strip or blister pack 
at accelerated conditions revealed significant reduction with time. 
Tables IV, V and VI show that most of aspirin chewable tablets formulations 
failed to pass free salicylic acid test after 2-3 months. 
Since aspirin is a moisture-sensitive drug, the findings could be attributed to 
formulation of aspirin with more hygroscopic excipients (starch, PVP and 
sorbitol). Water proof protection obtained by strip or blister pack made from 
PVC is not enough to protect acetylsalicylic acid from hydrolysis 
(Cunningham and Scattergood, 2001). 
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                            (a)                                                        (b) 
Figure.12 
Relationship between the results of content of aspirin in chewable tablet formulations 
after three months accelerated stability study when using: (a) Blister pack. (b) Strip 
pack 
 
4.2. Effervescent tablets: 
Table VII shows the complete layout of the experimental design adopted for 
the development of aspirin effervescent tablets to investigate for the possible 
influences that some formulation variables might have on the tablets’ 
performance. Respective formulations of the design appear in Table VIII. 
Table VII 
Lay out of the 32 full factorial design, with its coded and actual values, for development 
of aspirin effervescent tablets 
Formula code The mixture %
(X1) 
The ratio of acid to base 
(X2) 
EFF1 -1 -1 
EFF2                        +1 0 
EFF 3 0 +1 
EFF 4 -1 0 
EFF5 -1 +1 
EFF 6 +1 +1 
EFF 7 +1 -1 
EFF8 0 -1 
EFF9 0 0 
 Actual values 
Coded values X1 X2 
+1 40% 3.3:1 
0 27.1% 1:1 
-1 10% 1:3.3 
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Table VIII 
Formulations of aspirin effervescent tablets in the 32 factorial design. Amount of 
ingredients are equivalent to 100 tablets for each formulation 
Ingredients (g) Formulations 
 EFF 1 EFF2 EFF3 EFF4 EFF5 EFF6 EFF7 EFF8 EFF9 
Aspirin 7.50 7.50 7.50 7.50 7.50 7.50 7.50 7.50 7.50 
Citric acid 0.30 1.985 0.75 0.625 0.95 3.047 0.923 2.50 1.625 
Sodium bicarbonate 0.95 1.985 0.25 0.625 0.30 0.923 3.047 0.75 1.625 
Saccharin sodium 0.075 0.075 0.075 0.075 0.075 0.075 0.075 0.075 0.075 
Starch 0.925 0.925 0.925 0.925 0.925 0.925 0.925 0.925 0.925 
Talc 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
 
 
4.2.1. The influence of the ratio of citric acid to sodium bicarbonate and 
their mixture percent on the weight variation character of aspirin 
effervescent tablet formulations: 
                                      % of mixture of acid and base in the formula
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                                                                Fig. 13   
                                  The results of weight variation tests of aspirin 
                                                        effervescent tablet formulations                                                                  
Figure 13 is a line plot of the weight variation character of aspirin 
effervescent tablets. The plot shows that all formulations of acetylsalicylic 
acid effervescent tablets exhibit increase in standard deviation of tablet 
weights with increase in the percentage of mixture of citric acid and sodium 
bicarbonate (40%) in the formula and with increase in the amount of sodium 
bicarbonate with respect to citric acid. Since weight variation character of 
tablets is strongly related to the inconsistent flow of powder formulation 
during tablet production, the findings could be attributed to the non-uniform 
flow imparted to the powder formulation when sodium bicarbonate is 
present in large amount.  
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4.2.2. The influence of the ratio of citric acid to sodium bicarbonate and 
their mixture percent on friability character of aspirin effervescent 
tablet formulations: 
                                   % of mixture of acid and base in the formula
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Fig.14 
The results of friability tests of aspirin 
effervescent tablet formulations 
 
As evident from figure14 that with 6-10% level of starch as a binder, the 
loading level of the included citric acid has a profound influence (t’ test, 
p<0.05) in determining tablet friability. Most of tablets prepared with low 
loading level of citric acid showed less weight loss (satisfactory friability) 
compared to those containing high loading level. This might be due to the 
effectiveness of starch, at the specified loading level, to offset the attrition 
behavior of citric acid at low loading level. However, 6-10 % loading level 
of starch could possibly be insufficient to compensate for the attrition 
behavior of citric acid when present in large amount (Newman, 2002).  
  
4.2.3. The influence of the ratio of citric acid to sodium bicarbonate and 
their mixture percent on hardness of aspirin effervescent tablet 
formulations: 
Figure 15 is a line plot of hardness characteristic of aspirin effervescent 
tablets. The plot shows that almost all formulations revealed significant 
increase in hardness with increase in the amount of citric acid and decrease 
in the amount of sodium bicarbonate. Since the by product of effervescent 
reaction is water and starch, aspirin ,saccharin sodium are hygroscopic 
materials, water uptake increases to a level which can enhance the 
 65
compressional deformation and consolidation properties of citric acid upon 
application of minor compression load, thereby increasing the tablet 
strength(hardness)( Kontny and Conners 2006). 
On other hands, reduction in hardness with increase in the amount of sodium 
bicarbonate might be attributed to low compressibility of sodium 
bicarbonate (Lindberg and Hansson, 2002).  Increase in water uptake, 
caused by enhancing the effervescent reaction in the presence of both citric 
acid and aspirin, leads to decreased tablet strength (Uhumwangho and 
Okor, 2005).  
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Fig.15 
The results of hardness tests of aspirin 
effervescent tablet formulations 
 
4.2.4. The influence of the ratio of citric acid to sodium bicarbonate and 
their mixture percent on the content of aspirin and free salicylic acid 
tests in effervescent tablet formulations: 
Figure 16 is a line plot concerned with aspirin content % in effervescent 
tablets. The plot shows that almost all formulations did not comply with 
USP assay test and in all formulations increase in the percentage of mixture 
of citric acid and sodium bicarbonate leads to decrease in the amount of 
aspirin present.  In other words increase in the amount of sodium 
bicarbonate in the formula with respect to citric acid leads to decrease the 
amount of aspirin present. Aspirin hydrolysis is induced by the presence of 
large amount of base and absorption of atmospheric moisture (David, 2003) 
(Susan, 2006).  
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Fig.16 
The results of content% tests of aspirin in effervescent tablet formulations 
 
Table (IX) shows that all formulations did not comply with free salicylic 
acid test. In fact that increase in aspirin hydrolysis results in increase the 
amount of salicylic acid present. This finding indicates at all effervescent 
tablet formulations suffer from aspirin decomposition during processing. 
Table: IX 
The results of quality control tests of different formulations of aspirin 
 effervescent tablets at zero time 
 
Test EFF1 EFF2 EFF3 EFF4 EFF5 EFF6 EFF7 EFF8 EFF9 
Weight variation(±sd) 5.15 7.6 6.97 4.6 5.13 3.7 12.3 6.46 6.4 
Hardness(kp) 4.5 4.98 6.1 3.5 4.8 5.65 4.66 4.04 4.9 
Friability(%loss) 0.56 0.72 0.43 0.59 0.47 4.97 0.54 0.89 0.64 
Assay(content%) 148 65.3 95.2 85.04 122.56 70.25 54.2 50.3 72.9 
Free salicylic acid Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
Not 
comply 
 
Disintegration 
Not 
comply 
Not 
comply 
Not 
comply 
comply Not 
comply 
Not 
comply 
 
Comply Not 
comply 
Not 
comply 
 
 
4.2.5. The influence of the ratio of citric acid to sodium bicarbonate and 
their mixture percent on disintegration test of effervescent tablet 
formulations: 
Table (IX) shows that all formulations did not comply with disintegration 
test specified for effervescent tablets. This might be attributed to the 
initiation of effervescent reaction during manufacturing of tablets (Avani, 
2006).  
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4.2.6. Stability of aspirin effervescent tablet formulations: 
 
All formulations of aspirin effervescent tablet, packed in blister pack and 
stored at accelerated conditions (50 C° ± 2, 75% ±5 RH), exhibited the 
following problems, clear change in color and appearance of tablets, slight 
softening of tablets texture after 10 days, tablets adhere to blister pack, high 
water content and liquefied tablets after 20 days with odor of acetic acid and 
shining crystal.  Finally tablets lost their strength and became like a paste 
semisolid texture after one month with a lot of shining crystals and strong 
odor of acetic and salicylic acid. As well documented, small amount of 
water absorbed by effervescent tablets from atmosphere results in initiation 
of the reaction between citric acid and sodium bicarbonates. In essence the 
tablet will self-destroy because the by products of an effervescent reaction 
are water and carbon dioxide (Avani, 2006). 
Suggested reasons for these problems are tablets produced in uncontrolled       
humidity area. A maximum of 25 % RH  at controlled room temperature of 
25 Cº or less is usually sufficient to avoid problems caused by atmospheric 
moisture ( Lindberg and Hansson, 2002)in tablets containing hygroscopic 
materials ( aspirin, saccharin sodium and starch) and tablets packed in non 
protective PVC blister pack. PVC is good for oxygen barrier but can be 
permeable to water (Allen, 2002). 
 For commercial reasons and because of certain machine performance 
characteristic, the blister on most unit dose packaging is made of polyvinyl 
chloride.  For added moisture protection, polyvinylidene chloride (Saran) or 
polychlorotrifluoro ethylene (Aclar) films may be laminated to PVC. A 
blister formed from PVC is significantly more permeable than the material 
sheet form. 
Effervescent tablets are interesting pharmaceutical dosage forms offering 
some unique advantages when compared to simple tablets. Manufacturing 
process involves some critical steps which need to be addressed carefully 
during formulations and factory design (Stahl, 2006). 
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4.3. Conventional aspirin tablets: 
 
Composition of tablets: 
Aspirin 75 mg, starch 21.75 mg, saccharin sodium 0.75mg and talc powder 
2.5 mg in 100mg tablet. 
Table X 
The results of three months accelerated stability studies of aspirin conventional tablets 
Conditions: 50 C° ± 2, 75% ±5 RH 
Test Zero time One month Two months Three months 
Weight variation(±sd) 10.84 10.677 8.07 13 
Hardness(kp) 1.86 0.25 0.124 0.10 
Friability(%loss) 2.95 100 100  100 
Assay 99  100.8 97.3  94 
Free salicylic acid Comply  Not comply  Not comply  Not comply 
Disintegration comply comply comply comply 
 
Table (X) shows the results of three months accelerated stability study of 
conventional aspirin tablets. The table shows that conventional aspirin 
tablets formulated with starch, saccharin sodium and talc powder have 
undesirable physicochemical properties as follow: 
 
4.3.1. Weight variation: 
Table (X) shows that all tablets revealed high values of standard deviation of 
weights. This finding could be attributed to the non-uniform flow imparted 
to the powder formulation when starch is present in large amount. In 
general, it is the poor flow characteristics of starch incorporated which 
determines the overall flow behavior of the formula (Newman, 2002) (Chan 
and Chew, 2002). 
 
4.3.2. Hardness:  
Table (X) shows that all conventional tablets of aspirin packed in blister 
pack revealed low values of hardness despite that the tablet machine was 
adjusted to the highest pressure. This finding shows that starch in large 
amount act as disintegrant more than binder. 
The table also shows that the initial values of hardness decrease with time 
after storage at accelerated conditions; this might be attributed to the 
swallowing behavior (disintegration mechanism) of starch with increase in 
water uptake by the formulations (Rumbic and Kottke, 1996). 
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 4.3.3. Friability: 
It is evident from table (X) that all conventional aspirin tablets revealed high 
weight loss values initially and completely loose their integrity after storage 
at accelerated conditions for one month. This finding was attributed to weak 
binding effect and disintigrant action of starch when used in large amount 
(Newman, 2002). 
 
4.3.3. Aspirin content and free salicylic acid tests: 
Table (X) shows that all aspirin conventional tablets have passed the 
content% test after storage for three months at accelerated conditions and 
failed to pass free salicylic acid test.  
 
4.3.4. Disintegration test: 
Table(X) shows that all aspirin conventional tablets have passed the 
disintegration test.   
 
4.4. Upgraded aspirin (75 mg) chewable tablets formulation: 
From the results obtained for the three different aspirin (75mg) tablet dosage 
forms prepared (chewable, effervescent and conventional tablets), the 
chewable tablets was found to be the best.  It revealed the most acceptable 
limits of physicochemical specifications during quality control process. 
Table: XI 
The three formulations obtained from modification of formula CHF4 
 
Depending on the results discussed under (4.1.1) regarding the use of 
mixtures of mannitol and sorbitol to lower the cost and to enhance product 
stability, formula CHF4 was selected and modified by using a mixture of 
mannitol and sorbitol in ratio of 1:2, 1:1 and 2:1 as filler to obtain new three 
different formulations described in table XI. 
 
Tables XII to XV illustrate the results of three months accelerated stability 
study of the three formulations modified from formula CHF4. The results 
reveal that the three formulations after been subjected to accelerated stability 
conditions for three months show minor differences in weight variation, 
friability and a content% and a marked increase in hardness of formula 
CHF\Ingr Aspirin Mannitol Sorbitol Saccharin sodium Talc Starch 
CHF4A 75 mg 23.85 mg 11.91 mg 0.84 mg 2.4 mg 6 mg 
CHF4B 75 mg 17.88 mg 17.88 mg 0.84 mg 2.4mg  6 mg 
CHF4C 75 mg 11.91mg 23.85mg 0.84 mg 2.4 mg 6 mg 
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CHF4B when compared with the initial results. The free salicylic acid tests 
comply with specifications throughout the studies. It is concluded that 
aspirin (75mg) chewable tablets formulated with different mixture of 
mannitol and sorbitol can be stable for the claimed shelf life when stored 
below 30 Cº. 
Compressibility indices (CI) of formulae CHF4A, CHF4B and CHF4C are 
13.2%, 11.41% and 8.64 respestively. 
Table: XII 
The results of quality control tests of the three modified formulas 
CHF4A, CHF4B and CHF4C at zero time 
Formula Weight variation 
(SD ±) 
Friability (%) Hardness(kp) Content% Free.S.A 
CHF4A 5.15 0.62 3.94 104.4 Comply 
CHF4B 4.23 0.58 4.29 96 Comply 
CHF4C 5.16 0.59% 4.44 103.7 Comply 
 
Table: XIII 
The results of quality control tests of the three modified formulas 
CHF4A, CHF4B and CHF4C after one month accelerated stability study 
Conditions: 50 C° ± 2, 75% ±5 RH 
Formula Weight variation 
       (SD ±) 
Friability (%) Hardness(kp) Content% Free.S.A 
CHF4A 4.26 0.42 4.84 101 Comply 
CHF4B 4.0 0.21 4.04 99.89 Comply 
CHF4C 4.3 0.37 5.26 100.2 Comply 
 
Table: XIV 
The results of quality control tests of the three modified formulas 
CHF4A, CHF4B and CHF4C after two months accelerated stability study 
Conditions: 50 C° ± 2, 75% ±5 RH 
Formula Weight variation 
(SD ±) 
Friability (%) Hardness(kp) Content% Free. S.A 
CHF4A 3.92 0.42 4.6 96.36 Comply 
CHF4B 4.59 0.25 8.5 102.6 Comply 
CHF4C 4.26 0.42 5.32 95.5 Comply 
 
Table: XV 
The results of quality control tests of the three modified formulas 
CHF4A, CHF4B and CHF4C after three months accelerated stability study 
Conditions: 50 C° ± 2, 75% ±5 RH 
Formula/test Weight variation 
(SD ±) 
Friability (%) Hardness (kp) Content% Free. S.A 
CHF4A 4.76 0.303 3.83 100.9 Comply 
CHF4B 4.28 0.26 9.95 103.6 Comply 
CHF4C 4.89 0.4 3.58 97.8 Comply 
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Formula CHF4B was selected and upgraded in order to be formulated in 
large scale productions. 
 
4.4.1. Powder flow study:  
Powder flow of aspirin (CI) =10.1%   (excellent), mannitol (CI) = 20.7% 
(fair), sorbitol (CI) = 15.8 % (good), powdered mixture of (aspirin, mannitol 
and sorbitol)(CI)=30.4% (poor) and of granulated mixture of (aspirin, 
mannitol and sorbitol)(CI) =13%   (excellent) 
 
4.4.2. Mixing process: 
The results of mixing process of the three powders were as follows:  
The content of acetylsalicylic acid in 500 mg aspirin sample is equal to106.3 
%w/w, while in a mixture of 500mg aspirin, 500mg mannitol and 500mg 
sorbitol it was equal to 107.2 %. This indicated that mannitol and sorbitol 
have no effect on titration process. 
 For five samples, 1 gm of each, taken from different sites of powder bed, 
the content% of acetylsalicylic acid in sample I was equal to74.3, in sample 
II 80.2, in sample III 73.0%, in sample IV 67.6 and in sample V 42.3. The 
standard deviation (SD) was equal to ±14.7.  
The powder bed shows acceptable random mix of aspirin particles when 
mixed with a large amount of the two fillers. 
 
4.4.3. Manufacturing process study:  
Table: XVI 
The results of quality control tests of formula CHF4B when prepared by dry 
granulation and direct compression methods 
 
Tests of   CHF4B Production by dry  
granulation 
Production by direct 
compression 
Hardness(kp) 5.21  4.85  
Weight variation(±SD) 4 4.12 
Thickness(mm) 2.375  2.24  
Friability (%) 0.37  0.86  
Disintegration(min) 1 2.02  
Content% 99.08  100.1 
Free .S.A Comply comply 
 
Table XVI shows that formula CHF4B revealed, more acceptable values of 
quality control tests of tablets when it was prepared by dry granulation 
method rather than direct compression method. 
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4.4.4. Stability study for two batches of formula CHF4B: 
 
Table: XVII 
The results of six months accelerated stability studies of Batch .CT1 
Conditions: 40 C° ± 2, 75% ±5 RH 
Time in 
month 
Appearance Friability 
(%) 
Thickness 
(mm) 
Hardness 
(kp) 
Weight 
variation(±SD) 
S.A test Content% 
zero Complies 0.75 2.36 3.2 3.8 Complies 101.8 
1 Complies 0.74 2.4 4.05 1.7 Complies 99.08 
2 Complies 0.72 2.39 3.92 2.2 Complies 100.8 
3 Complies 0.66 2.369 3.93 0.3 Complies 96.4 
4 Complies 0.45 2.4 3.75 3.6 Complies 97.28 
5 Complies 0.56 2.45 2.5 4.3 Complies 98.18 
6 Not 
Complies 
2.3 2.445 3.6 0.3 Complies 95.5 
 
Tables XVII shows that after six months stability study of batch no. CT1 of 
formula CHF4B, produced by dry granulation methods, revealed 
insignificant differences in thickness, hardness, friability, weight variation 
and assay tests and comply with free salicylic acid and appearance tests 
throughout the five months accelerated stability studies.  However after six 
months the batch failed to pass appearance and friability test. 
 
Table: XVIII 
The results of six months accelerated stability studies of Batch.CT2 
Conditions: 40 C° ± 2, 75% ±5 RH 
Time in 
month 
Appearance Friability 
(%) 
Thickness 
(mm) 
Hardness 
(kp) 
Weight 
variation(±SD) 
S.A test Content% 
zero Complies 0.18 2.46 3.67 2.7 Complies 97.3 
1 Complies 0.41 2.47 3.6 1.9 Complies 102.7 
2 Complies 0.59 2.411 4.13 2.3 Complies 100.9 
3 Complies 0.23 2.42 3.75 2.2 Complies 99.08 
4 Complies 0.14 2.445 2.5 0.5 Complies 99.08 
5 Not 
Complies 
1.2 2.625 4.1 0.7 Not 
Complies 
97.3 
6 Not 
complies 
1.6 2.56 3.76 0.8 Not 
complies 
95.5 
 
Table XVIII shows that batch CT2 also revealed insignificant differences in 
thickness, hardness, friability, weight variation and assay tests and comply 
with free salicylic acid and appearance tests throughout the four months 
accelerated stability studies. After five to six months the batch failed to pass 
appearance, friability and free salicylic acid tests.     
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5. Conclusion and Recommendation 
 
Conclusion: 
In order to formulate aspirin 75 mg in tablet dosage forms, the preferred 
form is chewable tablets and the best filler was found to be a mixture of 
mannitol and sorbitol in different ratio. Hygroscopic binders such as PVP 
should be avoided and the tablets should be packed in well closed container 
to a void the effect of atmospheric moisture. 
Aspirin 75 mg effervescent tablets face a lot of problems during production 
when prepared from hygroscopic materials, in uncontrolled humidity area 
and not packed in suitable containers. 
Aspirin 75 mg conventional tablets formulated with starch, saccharin sodium 
and talc show undesirable physical properties. They contain a large amount 
of starch which imparts undesirable flow and binding properties. 
 Protection of tablet dosage form obtained by strip packs is better than that 
obtained by blister packs. 
 
Recommendations:  
 - Aspirin tablets should be formulated with nonhygroscopic excipients  
   and   packed in well- closed containers.  
 - The problems encountered effervescent formulations should be studied.  
 - To formulate the conventional tablet, starch should be modified. 
 - The bioavailability of the above dosage forms should be studied.  
 - Comparative studies of stability of the drugs packed in strip and  
    blister pack should be carried out. 
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